SCODiA Report by MLBI Lab

Integrated Single-Cell Analysis Unveils Genomic, Transcriptomic, and Microenvironmental Reprogramming in Human Kidney Cancer

This study provides a comprehensive single-cell analysis of human kidney tissue, comparing normal and renal cell carcinoma (RCC) conditions. We observe significant shifts in cell population composition, pervasive genomic instability (aneuploidy and recurrent CNVs, including EGFR amplification) in tumor epithelial cells, and extensive metabolic and signaling pathway reprogramming within the tumor microenvironment (TME). Key findings include critical cell-cell interactions (e.g., EREG-EGFR, CD47-SIRPA) that drive tumor progression and immune evasion, alongside changes in immune cell infiltration (e.g., increased macrophages, altered T cell ratios). These insights point toward novel diagnostic biomarkers and therapeutic targets for RCC.

Contents

0. Dataset overview
1. UMAP Visualization of Kidney scRNA-seq Data by Condition, Sample, Cell Type, and Ploidy
2. UMAP Visualization of Major Cell Type Scores and Annotations in Kidney Single-Cell RNA-seq
3. Celltype Subtype Marker Expression Analysis for Kidney Tissue
4. Analysis of Copy Number Variations in Renal Epithelial and Unassigned Cells
5. CNV-driven UMAP Visualization of Kidney Single-cell RNA-seq Data
6. Kidney Minor Cell Type Population Analysis Across Normal and Tumor Conditions
7. T 세포 아형 개체군 분석: 신장 종양 및 정상 조직 비교
8. Renal Epithelial and Unassigned Cell Ploidy Population Analysis in Kidney Samples
9. 신장 종양 미세환경 내 세포-세포 상호작용 분석
10. 신장 조직의 정상 및 종양 조건별 세포-세포 상호작용 분석
11. Cell-Cell Interactions Related to Immune Checkpoint and Cell Cycle Pathways in Normal and Tumor Kidney
12. Renal Epithelial Cell Condition-Specific Surfaceome Markers
13. Renal Epithelial Cell Gene Ontology (GSA) Analysis: Condition and Ploidy-Specific Pathway Enrichment
14. Gene Set Enrichment Analysis of Key Kidney Cell Types in Tumor Microenvironment
15. Discussion
16. Query List

0. Dataset overview

Dataset Summary:

• This dataset is an AnnData object containing single-cell RNA-seq data.
• It includes 26,502 cells and 22,483 genes from human Kidney tissue.
• Key observational metadata (obs columns) include total_UMI, sample, patient, condition (tumor, normal), disease_subtype, and various cell type annotations (celltype_major, celltype_minor, celltype_subset).
• Cell type annotations cover broad categories like Myeloid cell, T cell, Endothelial cell, and more specific subsets such as Macrophage (M1), T cell (Naive), and Proximal Convoluted Tubule S1_S2.
• Ploidy information (ploidy_dec: Aneuploid, Diploid) and CNV estimates (obsm['X_cnv']) are available.
• Precomputed results stored in uns include Cell-Cell Interaction (CCI) data, Differential Expression Gene (DEG) results, Gene Set Enrichment Analysis (GSEA) results, and Gene Ontology (GSA_up) results, all available per celltype_minor.
• Specifically, DEG, GSEA, and GSA/GO analyses are precomputed for selected celltypes: Endothelial cell, Macrophage, Renal Epithelial cell, Smooth muscle cell, and T cell CD4+.

1. UMAP Visualization of Kidney scRNA-seq Data by Condition, Sample, Cell Type, and Ploidy

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots of single-cell RNA-seq data from kidney tissue, comparing tumor and normal conditions. The UMAPs are colored by various metadata features: condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset. These visualizations provide an overview of the dataset structure, cell type distribution, and the relationship between cellular identity, tissue context (tumor/normal), and ploidy status within the low-dimensional embedding. The primary focus is on assessing annotation quality, cell identity, embedding structure, and sample/condition-level distributions.

Visual Summary

Condition

The UMAP plot colored by condition shows a clear separation between cells originating from tumor (purple) and normal (maroon) tissues. A large, consolidated cluster on the left side of the UMAP is predominantly composed of tumor cells, while the right side and some smaller, more dispersed clusters are enriched with normal cells. There is some degree of mixing in the central and upper-right regions, indicating shared cell populations or transitional states between conditions.

Sample

The sample UMAP displays good inter-sample mixing within the major clusters, suggesting that strong batch effects are not dominating the overall embedding structure. Different samples contribute to both tumor-rich and normal-rich regions, as expected given the experimental design. This indicates that the UMAP effectively captures biological variation rather than technical differences between samples. For example, samples like SI_18854 and SI_18855 are more prominent in the 'normal' clusters, while SI_23843 is largely found in the 'tumor' clusters.

Celltype_major

The celltype_major UMAP reveals distinct clustering of different cell types. Renal Epithelial cells (orange) form large clusters, especially on the left and upper-right, which largely overlap with the tumor-dominant regions. T cells (light blue) and Myeloid cells (light yellow/orange) are distributed across the UMAP, indicating their presence in both tumor and normal microenvironments. Endothelial cells (red), Stromal cells (light green), and B cells (maroon) also form well-defined clusters. There is an unassigned cluster (dark blue) which suggests some cells could not be confidently classified at this major level.

Celltype_minor

The celltype_minor UMAP provides a more granular view of cell populations. Key observations include:

• Proximal Tubule (light green) and Distal Tubule (orange), crucial renal epithelial components, are prominent in regions largely associated with normal tissue and diploid cells.
• Macrophage (light yellow) and T cell CD4+/T cell CD8+ (various shades of blue) populations are distributed widely, reflecting their diverse roles in both healthy and diseased states.
• Endothelial cells (red), Fibroblasts (light orange), and other stromal components show clear clustering, consistent with their distinct identities.

Ploidy_dec

The ploidy_dec UMAP shows a striking pattern: Aneuploid cells (maroon) almost exclusively reside within the large, contiguous clusters predominantly identified as tumor condition and Renal Epithelial cells. Conversely, Diploid cells (light yellow) are widely distributed across the remaining UMAP space, correlating with normal tissue and various non-malignant cell types. This strong concordance between aneuploidy, tumor condition, and specific cell types (likely malignant renal epithelial cells) is a key observation.

Celltype_subset

The celltype_subset UMAP further refines the cellular landscape, highlighting the diversity within major and minor cell types.

• Specific renal epithelial cell subsets like Proximal Convoluted Tubule S1_S2 (PCT_S1S2) and Proximal Straight Tubule S3 (PST_S3) are clearly delineated, mostly in diploid, normal regions.
• Various Macrophage (M1, M2A-D) and T cell (Naive, Cytotoxic, Treg, Th1/2/9/17/22, Tfh) subtypes are identifiable, indicating the complexity of the immune cell landscape within the kidney and tumor microenvironment.
• The unassigned population is still present at this resolution, suggesting areas of heterogeneity or cells requiring further characterization.

Biological Interpretation

The UMAP visualizations provide a comprehensive overview of the cellular composition and disease-associated changes in kidney tissue. The distinct separation of tumor and normal cells on the UMAP, strongly correlated with ploidy_dec, is a robust indicator of malignant transformation. Aneuploid cells are largely confined to tumor-specific clusters, which are dominated by Renal Epithelial cells. This is consistent with the understanding that renal cell carcinoma primarily originates from renal tubular epithelial cells, which often exhibit chromosomal instability and aneuploidy PubMed search: renal cell carcinoma aneuploidy.

The presence of diverse immune cell populations (T cells, Myeloid cells, B cells, NK cells) in both tumor and normal regions highlights their integral role in the kidney microenvironment, potentially contributing to immune surveillance in normal tissue and immune evasion or anti-tumor immunity within the tumor microenvironment. The differentiation into specific macrophage (M1, M2 subtypes) and T cell (cytotoxic, helper, regulatory) subsets suggests distinct functional states that warrant further investigation, especially in the context of their distribution in tumor versus normal compartments. M1 macrophages are generally pro-inflammatory and anti-tumorigenic, while M2 macrophages are often associated with tumor promotion and immune suppression GeneCards: CD68 (macrophage marker).

The detailed annotation of renal epithelial cells (e.g., Proximal Tubule, Distal Tubule, Podocytes, Collecting Duct) in the normal-enriched regions confirms the expected cellular architecture of healthy kidney tissue. Their relative absence or altered states in tumor regions, juxtaposed with the malignant renal epithelial cells, underscores the pathological changes driven by cancer.

The absence of strong sample-specific clustering (batch effects) indicates that the primary drivers of heterogeneity in this dataset are biological, related to cell type, condition, and ploidy status, rather than technical artifacts. This enhances confidence in the biological conclusions drawn from these embeddings.

Annotation Notes

• The consistency across different levels of annotation (major, minor, subset) and their alignment with biological conditions (normal/tumor) and ploidy status is generally good, supporting the quality of the cell type assignments.
• The strong correlation between Aneuploid cells, tumor condition, and Renal Epithelial cells provides strong confidence in distinguishing malignant cells from non-malignant cells and their tumor origin.
• The persistence of an "unassigned" category across celltype_major, celltype_minor, and celltype_subset annotations suggests that a small fraction of cells may represent rare populations, cells in transitional states, or those with ambiguous transcriptional profiles that warrant further, dedicated investigation for more precise classification.

2. UMAP Visualization of Major Cell Type Scores and Annotations in Kidney Single-Cell RNA-seq

[Analysis Visualization Results]...

Analysis Overview

This analysis provides a UMAP visualization of single-cell RNA-seq data from human kidney tissue, highlighting the confidence scores (HiCAT_major_score) for various major cell types, alongside the inferred ploidy status (ploidy_dec) and the final major cell type assignments (celltype_major). The primary goal is to assess the quality of cell type annotation and understand the distribution of ploidy states across the cell landscape.

Visual Summary

The UMAP plots display 26,502 cells embedded in a 2D space, with individual plots showing different features:

• HiCAT_major_score plots (T cell, B cell, Myeloid cell, Mast cell, Endothelial cell, Stromal cell, Renal Epithelial cell): Each of these plots colors cells based on their computed score for belonging to a specific major cell type.
• T cell: Shows a distinct cluster with high T cell scores (yellow/bright green) located primarily in the lower-central and upper-right regions of the UMAP.
• B cell: Exhibits a smaller, more diffuse cluster with high B cell scores, primarily in the lower-central region, overlapping partially with T cells.
• Myeloid cell: A well-defined cluster with high myeloid scores is visible in the upper-right quadrant.
• Mast cell: Shows a very sparse distribution with relatively low scores overall, with a few cells showing slightly elevated scores in the lower-central region.
• Endothelial cell: Displays a prominent cluster with high scores in the upper-left region and another smaller cluster in the upper-central region.
• Stromal cell: Shows a strong, localized cluster with high scores in the central-right region, extending towards the upper-right.
• Renal Epithelial cell: Exhibits several distinct clusters with high scores, particularly in the right-middle, lower-right, and central-left portions of the UMAP. These clusters appear to be well-separated from other cell types based on their scores.
• ploidy_dec plot: This plot categorizes cells into 'Aneuploid' (red), 'Diploid' (light yellow), and 'Unclear' (dark blue).
• A significant proportion of cells, primarily located in the right-middle and lower-right clusters, are identified as 'Aneuploid'.
• 'Diploid' cells are broadly distributed across the UMAP, occupying clusters distinct from the main aneuploid regions.
• A small number of 'Unclear' cells are scattered.
• celltype_major plot: This plot displays the final assigned major cell types using distinct colors, with a legend provided.
• The clusters of cells assigned to B cell (maroon), Endothelial cell (orange), Myeloid cell (light yellow), Renal Epithelial cell (beige), Stromal cell (light green), and T cell (teal) generally correspond well to the regions of high HiCAT scores observed in the individual major cell type score plots.
• Renal Epithelial cells (beige) are predominantly found in the right-middle and lower-right clusters.
• 'Unassigned' cells (dark purple) are present but constitute a minority, often located at the periphery or interfaces of major clusters.

Biological Interpretation

1. Robust Cell Type Annotation: The HiCAT_major_score plots demonstrate strong, localized signals for each major cell type. Cells with high scores for a particular type predominantly cluster together, and these high-score regions align very well with the final celltype_major assignments. This suggests that the cell type annotations are robust and well-supported by the underlying gene expression profiles, indicating good separation of distinct cellular identities in the UMAP embedding.
2. Heterogeneity of Renal Epithelial Cells: The HiCAT_major_score: Renal Epithelial cell plot shows multiple distinct clusters with high scores for this cell type. This heterogeneity is further reflected in the celltype_major plot, where multiple beige-colored clusters represent different populations within the Renal Epithelial cell lineage. This is expected in complex tissues like the kidney, where different segments of the nephron are comprised of specialized epithelial cells (e.g., Proximal Tubule, Distal Tubule, Collecting Duct, Podocytes, as seen in celltype_minor and celltype_subset contexts).
3. Aneuploidy as a Tumor Signature: Given that "Renal Epithelial cell" is identified as the "Tumor origin celltype" in the data context, the strong co-localization of 'Aneuploid' cells with the Renal Epithelial cell clusters in the ploidy_dec plot is a critical finding. Aneuploidy, the presence of an abnormal number of chromosomes, is a hallmark of many cancers, including renal cell carcinoma PubMed search: aneuploidy renal cell carcinoma. This observation strongly suggests that the identified aneuploid Renal Epithelial cell clusters likely represent the malignant tumor cells. Conversely, the diploid cells are distributed across other non-epithelial clusters and some epithelial clusters, likely representing normal kidney cells and the tumor microenvironment.
4. Immune and Stromal Compartments: Distinct clusters for T cells, B cells, Myeloid cells, Endothelial cells, and Stromal cells are clearly resolved. These populations represent the immune infiltrate, vasculature, and structural components of the kidney and the tumor microenvironment. The spatial separation of these clusters from the main Renal Epithelial cell clusters confirms their distinct transcriptional profiles. The presence of these immune cell populations indicates an immune response, which is common in tumors PubMed search: tumor immune microenvironment kidney.
5. Mast Cell Distribution: The low scores and diffuse distribution of 'Mast cell' scores suggest either a very low abundance of these cells in the dataset or that their transcriptional profile is not strongly distinct enough to form a well-defined cluster under the current major cell type scoring, perhaps due to their potential overlap with other myeloid populations or scarcity.

Annotation Notes

• The UMAP visualization effectively demonstrates the quality and consistency of the major cell type annotations. The high agreement between the computed cell type scores and the final assigned labels indicates a reliable cell type calling process.
• The clear separation of cell types on the UMAP, combined with the distinct high-score regions for each, provides confidence in the biological distinctiveness of the identified populations.
• The unassigned cells are minimal and generally located at cluster boundaries, suggesting that most cells have been confidently categorized.
• The Unclear category for ploidy_dec is also minimal, indicating high confidence in ploidy inference for most cells.

3. Celltype Subtype Marker Expression Analysis for Kidney Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot visualizing the expression of marker genes across various celltype_subset populations identified in human kidney single-cell RNA sequencing data. The plot serves as a critical quality control and validation step for the cell type annotations, confirming whether the assigned cell identities are supported by the expression patterns of known and discovered cell type-specific genes. The size of each dot corresponds to the fraction of cells within a group expressing the gene, while the color intensity reflects the mean expression level of the gene in that group. Only surfaceome genes with a score cutoff of 0.25 and fold change cutoff of 1.5 were considered as markers for plotting.

Visual Summary

The dot plot displays 27 celltype_subset groups on the y-axis and 120 selected marker genes on the x-axis.

• Distinct Marker Expression: Most celltype_subset groups exhibit distinct clusters of highly expressed marker genes, indicated by large, dark red dots primarily aligned along the diagonal or in block-like patterns. This suggests good separation and unique molecular signatures for many annotated cell types.
• Cell Type Grouping: The plot features brackets above the gene names, grouping markers that are particularly enriched within broader cell lineages (e.g., specific T cell subsets, macrophage subtypes). Similarly, brackets on the y-axis group related cell types, indicating shared but also distinct marker profiles within these groups.
• Fraction of Expressing Cells vs. Mean Expression: The legend clarifies that dot size represents the fraction of cells expressing a gene (from 0% to 80%+), and color intensity (Reds heatmap) represents the mean expression level (from 0.0 to 1.0). This dual encoding allows for assessing both prevalence and magnitude of expression.
• Cell Counts: A bar chart on the right side of the plot indicates the total number of cells belonging to each celltype_subset, ranging from 41 (ILC1) to 3603 (Endothelial cell). This information helps in interpreting marker specificity with respect to the abundance of each cell type.
• Identifiable Marker Clusters: Clear examples include:
• Kidney epithelial cells: Collecting Duct Principal cells show expression of KCNJ1, AQP2, SCNN1A. Intercalated cells show ATP6V1G3, FOXI1, RCAN2. Proximal Convoluted Tubule cells show SLC3A1, SLC5A1, ASL. Podocytes show NPHS1, NPHS2, CLU.
• Immune cells: Macrophage subtypes (M1, M2A, M2B, M2C) display differential expression of CD86, CD36, CD83, MSR1. T cell subsets (Cytotoxic, Naive, Tfh, Th1, Th17, Th2, Treg) show distinct patterns of CD8A, CD8B, GZMK, SELL, PDCD1, IFNG, IL17RA, GATA3, FOXP3, CTLA4. Plasma cells are characterized by JCHAIN, MZB1, PRDM1, SDC1. NK cells show KLRD1, NCR3, FCGR3A.
• Stromal/Endothelial cells: Fibroblasts express COL1A1, COL3A1, COL6A2, DCN, LUM. Smooth muscle cells express ACTA2, MYH11, MYL9, TAGLN. Endothelial cells, including tip cells, express ESM1, ANGPT2.

Biological Interpretation

The marker gene expression patterns largely confirm the assigned celltype_subset annotations, demonstrating the robustness of the single-cell clustering and cell type identification in the kidney tissue.

1. Renal Epithelial Cells:

• Collecting Duct Principal cells are clearly identified by markers like AQP2 (aquaporin-2), crucial for water reabsorption, and SCNN1A (epithelial sodium channel subunit alpha), involved in sodium balance. KCNJ1 (ROMK channel) is also highly expressed [1, 2].
• Intercalated cells show distinct expression of ATP6V1G3 (V-type proton ATPase subunit), FOXI1 (forkhead box protein I1), and RCAN2, consistent with their role in acid-base homeostasis in the collecting duct [3].
• Proximal Convoluted Tubule S1_S2 cells are marked by transporters such as SLC3A1 and SLC5A1 (sodium-glucose cotransporter 1), reflecting their primary role in reabsorption [4].
• Podocytes display high expression of NPHS1 (nephrin) and NPHS2 (podocin), essential components of the glomerular filtration barrier, confirming their identity [5, 6].

2. Immune Cells:

• Macrophage subtypes (M1, M2A, M2B, M2C) exhibit both shared and distinct markers, consistent with macrophage plasticity and diverse functional states. For instance, CD86 is often associated with M1 activation, while CD83 and MSR1 (macrophage scavenger receptor 1) can be found in M2-like macrophages [7]. The observed differential expression supports the sub-categorization.

T cell subsets are well-demarcated

• Cytotoxic T cells express CD8A/CD8B and cytotoxic granule components like GZMK and GZMB.
• Naive T cells show high expression of SELL (L-selectin/CD62L).
• T follicular helper (Tfh) cells express PDCD1 (PD-1) and CD40LG (CD40 ligand).
• Th1 cells are characterized by IFNG (interferon-gamma) and IFNGR1.
• Treg cells express key suppressive markers FOXP3, CTLA4, and IL2RA (CD25), validating their identity [8].
• Plasma cells are clearly identified by markers involved in antibody production and secretion, such as JCHAIN, MZB1, PRDM1 (Blimp-1), and SDC1 (CD138) [9].
• NK cells show characteristic expression of KLRD1 (CD94), NCR3 (NKp30), and FCGR3A (CD16) [10].

3. Stromal and Endothelial Cells:

• Fibroblasts show expected expression of extracellular matrix components and related genes like COL1A1, COL3A1, COL6A2 (collagens), DCN (decorin), and LUM (lumican) [11].
• Smooth muscle cells are identified by contractile proteins such as ACTA2 (alpha-smooth muscle actin), MYH11 (myosin heavy chain 11), MYL9, and TAGLN (transgelin) [12].
• Endothelial cells, including Endothelial tip cells, express markers like ESM1 (endothelial cell-specific molecule 1) and ANGPT2 (angiopoietin-2), important for angiogenesis and vascular integrity [13].

The overall clarity of marker expression patterns for most cell types indicates a high quality of cell type annotation for these kidney single-cell data. The distinct clusters of markers strongly support the biological identities assigned to these celltype_subset populations.

Annotation Notes

The dot plot largely confirms the quality of the celltype_subset annotations based on the expression of known and highly specific marker genes. The distinct expression profiles observed across different cell subsets, especially within the complex immune and renal epithelial compartments, suggest robust cell clustering and accurate labeling. However, it's worth noting any minor overlaps or less distinct patterns for certain markers that might suggest functional plasticity or shared lineage characteristics between very closely related cell types. For example, some markers might show low-level expression in adjacent cell types, which is not uncommon in biological systems and can represent a continuum of cell states rather than strict boundaries.

References

1. AQP2: PubMed search for "aquaporin 2 kidney collecting duct" https://pubmed.ncbi.nlm.nih.gov/?term=aquaporin+2+kidney+collecting+duct
2. KCNJ1: GeneCards entry for KCNJ1 https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNJ1
3. Intercalated cell markers: PubMed search for "intercalated cell markers kidney" https://pubmed.ncbi.nlm.nih.gov/?term=intercalated+cell+markers+kidney
4. Proximal Tubule markers: GeneCards entry for SLC5A1 https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC5A1
5. NPHS1: GeneCards entry for NPHS1 https://www.genecards.org/cgi-bin/carddisp.pl?gene=NPHS1
6. NPHS2: GeneCards entry for NPHS2 https://www.genecards.org/cgi-bin/carddisp.pl?gene=NPHS2
7. Macrophage markers: PubMed search for "M1 M2 macrophage markers" https://pubmed.ncbi.nlm.nih.gov/?term=M1+M2+macrophage+markers
8. Treg markers: PubMed search for "FOXP3 CTLA4 IL2RA Treg" https://pubmed.ncbi.nlm.nih.gov/?term=FOXP3+CTLA4+IL2RA+Treg
9. Plasma cell markers: PubMed search for "plasma cell markers JCHAIN SDC1 PRDM1" https://pubmed.ncbi.nlm.nih.gov/?term=plasma+cell+markers+JCHAIN+SDC1+PRDM1
10. NK cell markers: PubMed search for "NK cell markers KLRD1 NCR3 FCGR3A" https://pubmed.ncbi.nlm.nih.gov/?term=NK+cell+markers+KLRD1+NCR3+FCGR3A
11. Fibroblast markers: PubMed search for "fibroblast markers COL1A1 DCN LUM" https://pubmed.ncbi.nlm.nih.gov/?term=fibroblast+markers+COL1A1+DCN+LUM
12. Smooth muscle cell markers: GeneCards entry for ACTA2 https://www.genecards.org/cgi-bin/carddisp.pl?gene=ACTA2
13. Endothelial cell markers: PubMed search for "endothelial cell markers ESM1 ANGPT2" https://pubmed.ncbi.nlm.nih.gov/?term=endothelial+cell+markers+ESM1+ANGPT2

4. Analysis of Copy Number Variations in Renal Epithelial and Unassigned Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) in Renal Epithelial cell and unassigned cell populations from kidney single-cell RNA-seq data. Cells were grouped by sample, and CNV estimates (log2(CNR)) were visualized across genomic spots. A summary of significantly amplified/deleted cytogenetic bands and their frequencies across samples was also generated. The primary goal is to identify recurrent genomic alterations that might characterize these cell populations, especially in the context of tumor conditions. This also serves to validate the ploidy_dec and tumor origin celltype annotations by identifying expected patterns of genomic instability.

Visual Summary

The CNV heatmap displays log2(CNR) values for individual cells grouped by sample and ploidy status (Diploid or likely Aneuploid, based on ploidy_dec). Genomic spots are arranged along the x-axis, representing the chromosomal order from chr1 to chr22.

Heatmap (log2(CNR)):

• Several cell_group entries are prefixed with "Diploid" (e.g., Diploid SI_18855). These groups generally exhibit a relatively stable genomic profile, with log2(CNR) values centered around zero, indicating a near-diploid state and minimal large-scale CNVs.
• In contrast, other cell groups (e.g., SI_18854, SI_19703, SI_21561, SI_22369, SI_22604) show extensive and chaotic patterns of genomic alterations, with distinct regions of amplification (red/yellow) and deletion (blue) across multiple chromosomes. This widespread genomic instability is characteristic of aneuploidy and malignancy.
• Notably, samples like SI_22604 and SI_22369 display particularly aggressive patterns of CNVs, with large, continuous stretches of amplification and deletion.
• Commonly altered regions visually apparent in aneuploid samples include segments on chromosome 1, 5, 7, and 14, among others.

Summary Heatmap and Frequency Plot:

• The summary heatmap on the left quantifies the frequency of significant CNV events within specific cytogenetic bands across different samples. Darker blue indicates a higher frequency of alterations in that region.
• The accompanying bar plot on the right summarizes the overall frequency of these significant CNV events across all analyzed cells and samples.

Several cytogenetic bands show recurrent alterations with notable frequencies

1p34.2:1p32.3 (frequency 0.33)

5q23.1:5q31.3 (frequency 0.44)

• 7p13:7q11.23 (EGFR) (frequency 0.33) - This region, containing the *EGFR* gene, shows significant recurrent alteration.

14q11.2:14q12 (frequency 0.44)

16q12.2:16q22.1 (frequency 0.33)

• Samples SI_18854, SI_22368, SI_22605, and SI_23459 appear to contribute significantly to the observed frequencies for several of these recurrent CNV regions.

Biological Interpretation

The observed CNV patterns provide strong biological insights into the Renal Epithelial cell and unassigned populations, particularly in the context of kidney cancer.

• Evidence of Malignancy and Aneuploidy: The stark contrast between "Diploid" and highly aneuploid cell groups within the analyzed samples strongly suggests the presence of malignant cells. Given that Renal Epithelial cell is annotated as a Tumor origin celltype, the widespread and aggressive CNVs observed in the non-Diploid samples are consistent with tumor-associated genomic instability. This provides strong validation for the ploidy_dec annotation.
• Tumor Cell Identification: The unassigned cells, when showing similar aneuploid patterns to Renal Epithelial cell populations from tumor samples, likely represent tumor cells that could not be precisely classified into a specific normal cell type due to disease-associated transcriptional changes or dedifferentiation. This highlights the utility of CNV analysis in identifying tumor cells independent of gene expression-based annotation.

Recurrent Cancer-Associated CNVs:

• _EGFR_ amplification (7p13:7q11.23): The significant and recurrent alteration in the 7p13:7q11.23 region, which harbors the *EGFR* gene, is highly relevant. *EGFR* (Epidermal Growth Factor Receptor) is a well-established oncogene whose amplification or overexpression is common in various cancers, including renal cell carcinoma (RCC), where it promotes cell proliferation, survival, and metastasis [PubMed search: "EGFR renal cell carcinoma" - PubMed Search].
• Chromosome 1q amplification: Amplification of regions on chromosome 1q, such as 1q32.3, is a common genomic aberration in many cancers and is often associated with aggressive disease behavior [GeneCards: 1q amplification - GeneCards].
• Chromosome 5q amplification: Alterations in 5q are frequently implicated in various malignancies and can contribute to tumor progression.
• Chromosome 14q and 16q alterations: Recurrent changes on chromosomes 14q and 16q are also frequently observed in RCC. For instance, losses on 14q and 16q are known to occur in RCC and are often associated with tumor progression [PubMed search: "14q loss renal cell carcinoma" - PubMed Search], [PubMed search: "16q loss renal cell carcinoma" - PubMed Search]. The summary indicates these regions are recurrently altered, which could be either amplifications or deletions depending on the specific event. The consistent presence in a subset of samples suggests their pathogenic role.

Clinical or Translational Implications

The findings have several potential clinical and translational implications for renal cancer:

• Biomarker Identification: The recurrent CNVs, particularly EGFR amplification and alterations on 1q, 5q, 14q, and 16q, could serve as prognostic or diagnostic biomarkers for kidney cancer. Detecting these specific genomic changes in patient samples could aid in early diagnosis, risk stratification, or predicting disease aggressiveness.
• Therapeutic Targeting: The identification of EGFR amplification is particularly important. EGFR is a well-established therapeutic target, and its amplification could indicate a subset of renal cancer patients who might benefit from EGFR inhibitor therapies. Further investigation would be needed to validate the clinical utility of such targeted approaches in this patient cohort.
• Tumor Heterogeneity: The presence of both diploid and highly aneuploid cells within the same samples underscores the genomic heterogeneity within kidney tumors. Understanding this heterogeneity is crucial for developing effective treatment strategies, as different subclones within a tumor may respond differently to therapy.
• Annotation Validation: The clear CNV patterns observed effectively validate the ploidy_dec annotation and reinforce the classification of Renal Epithelial cell as a Tumor origin celltype, especially for cells displaying aneuploidy. This provides confidence in downstream analyses relying on these cell type classifications.

5. CNV-driven UMAP Visualization of Kidney Single-cell RNA-seq Data

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP embeddings derived from single-cell RNA-seq data, specifically incorporating Copy Number Variation (CNV) estimates to define the embedding structure. The UMAP plots are colored by various metadata annotations: major cell type, minor cell type, ploidy status (Aneuploid/Diploid), condition (tumor/normal), and individual sample. The primary goal is to visualize cell population structure based on CNV patterns and assess the consistency of cell annotations and condition-specific distributions with ploidy status.

Visual Summary

Cell Type Distribution

• celltype_major UMAP: The UMAP displays distinct clusters for major cell types. 'Renal Epithelial cell' forms a prominent, large cluster on the right side of the embedding (yellow to light green). 'T cell' and 'Myeloid cell' populations are also well-defined, generally occupying the upper-middle and lower-left regions, respectively, showing some intermixing. 'Endothelial cell' and 'Stromal cell' clusters are visible, primarily on the left side. The 'unassigned' cells are scattered but tend to co-localize with other cell types, suggesting they might be unclassified cells within those broader populations or perhaps unique cell states.
• celltype_minor UMAP: This plot provides a more granular view. Within the large 'Renal Epithelial cell' major cluster, minor types like 'Proximal Tubule', 'Distal Tubule', 'Collecting Duct Principal cell', and 'Podocyte' are visible. 'Macrophage' (part of Myeloid) and various 'T cell' subtypes (CD4+, CD8+) form distinct groups, consistent with their major cell type assignments.

Ploidy Status

• ploidy_dec UMAP: A striking pattern is observed where 'Aneuploid' cells (dark red) predominantly form specific clusters, notably one large cluster on the right, which spatially corresponds to the 'Renal Epithelial cell' populations. Another smaller, distinct 'Aneuploid' cluster is seen towards the lower-left. Conversely, 'Diploid' cells (light yellow) constitute the vast majority of the remaining cell populations, encompassing immune cells (T cells, Myeloid cells), stromal cells, and endothelial cells. There are very few 'Unclear' cells.

Condition and Sample Distribution

• condition UMAP: 'Tumor' cells (dark blue) overlap significantly with the 'Aneuploid' clusters, particularly the large 'Renal Epithelial cell' cluster on the right. This strongly suggests that the aneuploid cells largely originate from the tumor. 'Normal' cells (dark red in this plot, distinct from ploidy 'Aneuploid' color) are more distributed across the 'Diploid' clusters, indicating the presence of normal tissue-resident cells and infiltrating immune cells in both conditions, but with a clear dominance of tumor cells in the aneuploid regions.
• sample UMAP: The UMAP shows a mix of cells from different samples (SI_18854 to SI_23843) across the embedding. While some samples show relative enrichment in specific regions (e.g., SI_23843 [dark blue] seems more associated with the large aneuploid/tumor cluster), cells from multiple samples contribute to most major clusters. This indicates that the observed biological variations (cell types, ploidy, condition) are not solely driven by a single sample or strong batch effects at the embedding level.

Biological Interpretation

The UMAP embedding, constructed with CNV estimates (cnv=True), effectively segregates cells primarily based on their genomic integrity.

1. Malignant Cell Identification: The strong co-localization of 'Aneuploid' cells with the 'Renal Epithelial cell' major cluster and 'tumor' condition cells strongly suggests that these aneuploid renal epithelial cells represent the malignant epithelial cells of kidney cancer. Renal cell carcinoma (RCC), the most common form of kidney cancer, is characterized by significant chromosomal instability and aneuploidy PubMed search: renal cell carcinoma aneuploidy.
2. Tumor Microenvironment Composition: The 'Diploid' cell clusters, which largely correspond to immune cells (T cells, Myeloid cells), endothelial cells, and stromal cells, are present in both tumor and normal conditions. This reflects the complex tumor microenvironment (TME) in which non-malignant cells, including immune infiltrates and supporting stromal/endothelial cells, interact with the tumor cells. These diploid cells are also found in 'normal' kidney tissue, as expected for healthy tissue composition.
3. Heterogeneity within Tumor: The presence of multiple aneuploid clusters (e.g., the large renal epithelial cluster and a smaller lower-left cluster) could indicate distinct subclones or varying degrees of chromosomal aberrations within the tumor cell population. The data context notes "Tumor origin celltype: unassigned, Renal Epithelial cell", which aligns perfectly with the observation that the primary aneuploid population is renal epithelial.
4. Robustness of Annotations: The consistency between the CNV-driven embedding, ploidy status, and cell type/condition annotations reinforces the quality of the cell type assignments. Immune, stromal, and endothelial cells maintain their diploid status and distinct clustering, as expected for non-malignant cells.

Annotation Notes

• Cell Identity Confirmation: The clear separation of cell types, especially the distinction between 'Renal Epithelial cell' (which contains the malignant population) and other stromal/immune cells, is well-supported by the CNV-driven embedding. This suggests that the cell type annotations are robust and biologically meaningful in the context of genomic stability.
• Embedding Structure: The UMAP effectively captures the primary biological difference in this dataset: the presence of aneuploid, likely malignant, cells versus diploid, non-malignant cells. The cnv=True parameter in embed_cfg successfully highlights this genomic distinction.
• Condition and Ploidy Alignment: The strong correlation between 'tumor' condition and 'Aneuploid' status, predominantly within the 'Renal Epithelial cell' cluster, provides strong validation for both the ploidy inference and the condition labeling. This indicates that the "tumor" samples contain a significant proportion of aneuploid cells, consistent with cancer biology.
• Sample Integration: The distribution of samples across the UMAP suggests good integration, as no single sample dominates a major cluster in a way that would indicate a strong batch effect confounding the biological signals.

6. Kidney Minor Cell Type Population Analysis Across Normal and Tumor Conditions

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 사용하여 신장 조직 내의 마이너 세포 유형 구성을 '정상(normal)' 및 '종양(tumor)' 조건별로 비교한 결과입니다. 각 조건 내 개별 샘플에 걸쳐 각 마이너 세포 유형의 상대적 비율을 막대 그래프로 시각화하여, 질병 상태에 따른 세포 환경의 변화를 파악하는 데 중점을 둡니다.

Visual Summary

제공된 바 플롯은 정상 및 종양 신장 샘플 간의 마이너 세포 유형 구성에서 뚜렷한 차이를 보여줍니다.

정상 신장 조직:

• 대부분의 정상 샘플에서는 Proximal Tubule (옅은 녹색) 및 Distal Tubule (주황색) 세포가 가장 높은 비율을 차지하며, 이는 건강한 신장 실질 세포의 지배적인 역할을 반영합니다.
• Endothelial cell (옅은 주황색) 및 Macrophage (옅은 노란색)도 상당한 비율로 존재하며, 이는 신장의 혈관 구조와 상주 면역 세포를 나타냅니다.
• T cell CD4+ (청록색) 및 T cell CD8+ (짙은 파란색)와 같은 면역 세포는 소수이지만 일관되게 존재합니다.
• 일부 샘플에서는 'unassigned' (짙은 남색) 세포의 비율이 꽤 높게 나타나, 특정 마이너 세포 유형으로 명확히 분류되지 않은 세포 집단이 있음을 시사합니다.

종양 신장 조직:

• 정상 신장 실질 세포의 감소: Proximal Tubule 및 Distal Tubule 세포의 비율이 정상 샘플에 비해 대부분의 종양 샘플에서 현저하게 감소했습니다. 이는 종양 침윤으로 인한 정상 조직의 파괴 또는 대체와 일치합니다.

면역 세포 침윤 증가:

• Macrophage (옅은 노란색)의 비율이 종양 샘플에서 상당히 증가했습니다. 일부 샘플(예: SI_21561, SI_23843, SI_18855)에서는 전체 세포의 상당 부분을 차지합니다.
• T cell CD8+ (짙은 파란색)의 비율 또한 많은 종양 샘플에서 눈에 띄게 증가했습니다. 이는 종양 미세환경 내 세포독성 T세포 침윤을 시사합니다.
• T cell CD4+ (청록색) 및 Plasma cell (연두색), B cell (짙은 빨간색) 등 다른 면역 세포들도 종양 샘플에서 더 높은 비율로 관찰됩니다.
• 기질 세포의 변화: Fibroblast (옅은 주황색)의 비율도 일부 종양 샘플에서 증가하여, 종양 미세환경에서 암 관련 섬유아세포(CAFs)의 역할을 반영할 수 있습니다.
• 'unassigned' 세포의 변화: 'unassigned' (짙은 남색) 세포의 비율은 종양 샘플에서도 높게 유지되거나, 일부 샘플(예: SI_19703)에서는 훨씬 더 높아집니다. 이는 변형된 신장 상피 세포 또는 다른 유형으로 명확히 분류되지 않은 종양 세포를 포함할 수 있음을 시사합니다.
• 샘플 간 이질성: 종양 샘플 내에서 세포 유형 구성의 높은 이질성이 관찰됩니다. 예를 들어, 일부 종양 샘플은 Macrophage가 지배적인 반면, 다른 샘플은 T cell이 더 많거나 'unassigned' 세포의 비율이 더 높습니다.

Biological Interpretation

이러한 세포 유형 구성의 변화는 신장 종양 미세환경(TME)의 재구성을 명확하게 보여줍니다.

1. 정상 신장 실질 세포의 감소 및 기능 상실: Proximal Tubule 및 Distal Tubule과 같은 주요 신장 상피 세포의 현저한 감소는 종양 발달이 정상 신장 조직의 구조적 및 기능적 완전성을 침해한다는 것을 나타냅니다.
2. 면역 세포 침윤 및 종양 미세환경 형성:

• 대식세포 (Macrophage)의 증가: 종양 미세환경에서 대식세포, 특히 종양 관련 대식세포(TAMs)는 종양 성장, 혈관신생, 면역억제 및 전이를 촉진하는 데 중요한 역할을 합니다 PubMed search: tumor associated macrophages kidney cancer.
• T 세포 침윤 (T cell CD4+, T cell CD8+): CD8+ T 세포는 항종양 면역 반응의 핵심 조절자이며, 그들의 침윤은 더 나은 예후와 관련될 수 있습니다. 그러나 TME 내 면역억제 신호로 인해 기능 장애가 발생할 수도 있습니다. CD4+ T 세포는 다양한 하위 집합(예: Th1, Th2, Treg)으로 나뉘며, 그 역할은 맥락에 따라 다릅니다. TME 내 Plasma cell 및 B cell의 증가는 체액성 면역 반응과 관련될 수 있습니다.

3. 기질 재형성 (Stromal Remodeling): Fibroblast의 증가는 암 관련 섬유아세포(CAFs)의 존재를 시사합니다. CAFs는 세포외 기질(ECM)을 재형성하고, 종양 세포 성장 및 약물 내성을 촉진하는 사이토카인 및 성장 인자를 분비하여 종양 진행에 기여합니다 GeneCards: FAP.
4. 'unassigned' 집단의 중요성: 데이터 컨텍스트에서 'Tumor origin celltype'이 'unassigned' 및 'Renal Epithelial cell'로 명시되어 있으므로, 종양 샘플의 'unassigned' 집단은 악성 신장 상피 세포를 포함할 가능성이 높습니다. 이러한 세포들은 변형되거나 탈분화되어 정상 신장 상피 세포 유형으로 명확하게 분류되지 않았을 수 있습니다.

Clinical or Translational Implications

이러한 세포 구성 분석 결과는 신장 종양의 진단, 예후 및 치료 전략 개발에 중요한 시사점을 제공합니다.

• 바이오마커 발굴: 종양 미세환경에서 현저하게 증가하는 Macrophage 또는 특정 T cell 아형의 비율은 잠재적인 진단 또는 예후 바이오마커로 활용될 수 있습니다.
• 면역치료 표적: Macrophage 및 T 세포 집단의 변화는 면역관문억제제(immune checkpoint inhibitors) 또는 TME를 조절하는 표적 치료의 잠재적 반응을 예측하는 데 도움이 될 수 있습니다 PubMed search: immunotherapy kidney cancer TME. 예를 들어, 높은 CD8+ T 세포 침윤은 면역치료에 대한 반응을 시사할 수 있지만, 동시에 Macrophage 또는 Treg 세포의 증가는 면역 억제 환경을 나타낼 수 있습니다.
• 약물 내성 메커니즘: Fibroblast의 증가와 같은 기질 구성 요소의 변화는 종양의 약물 내성 및 전이 능력과 관련이 있을 수 있으며, 이는 섬유아세포를 표적으로 하는 치료법의 개발로 이어질 수 있습니다.
• 종양 이질성 이해: 종양 샘플 간의 높은 세포 유형 이질성은 맞춤형 치료 전략의 필요성을 강조하며, 각 환자의 종양 특이적 TME를 고려하는 것이 중요함을 시사합니다.
• 'unassigned' 세포의 추가 특성 분석: 'unassigned' 집단이 종양 세포를 포함할 가능성이 높으므로, 이 집단에 대한 추가적인 분석(예: CNV 분석, 종양 특이적 마커 발현)은 종양 세포의 특성과 종양 미세환경과의 상호작용을 더 깊이 이해하는 데 필수적입니다.

7. T 세포 아형 개체군 분석: 신장 종양 및 정상 조직 비교

[Analysis Visualization Results]...

Analysis Overview

이 분석은 신장 조직에서 얻은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 사용하여, 정상 및 종양 조건별 T 세포 및 관련 림프구 아형의 개체군 비율을 시각화합니다. 구체적으로, 각 샘플에서 T cell (CD4+), T cell (CD8+), NK cell, 및 ILC의 상대적인 비율 변화를 보여줍니다.

Visual Summary

제공된 바 플롯은 신장 조직에서 정상(normal)과 종양(tumor) 조건 간의 T 세포 아형 및 관련 림프구 개체군 구성에 뚜렷한 차이를 보여줍니다.

• 정상 조직: 정상 샘플(SI_21256, SI_22369, SI_18856, SI_21255, SI_22605)에서는 일반적으로 T cell CD8+ (연녹색) 세포가 가장 높은 비율을 차지하며, T cell CD4+ (연노란색) 세포도 상당한 부분을 구성합니다. NK cell (주황색) 및 ILC (자주색)는 비교적 적은 비율로 나타납니다. 샘플 간에도 T cell CD4+와 CD8+ 비율에 약간의 변동성이 관찰됩니다.
• 종양 조직: 종양 샘플(SI_18855, SI_18854, SI_23459, SI_22604, SI_21561, SI_23843, SI_22368, SI_19703)에서는 정상 조직과 비교하여 T cell CD8+의 상대적 비율이 전반적으로 현저히 감소한 경향을 보입니다. 반면, T cell CD4+의 비율은 많은 종양 샘플에서 증가하여, 일부 샘플에서는 가장 우세한 T 세포 아형이 됩니다. 특히 SI_23459, SI_22604, SI_23843, SI_22368, SI_19703과 같은 샘플에서 T cell CD4+의 높은 비율이 두드러집니다. NK cell 및 ILC의 비율은 종양 샘플에서 변동성이 크며, 일부 샘플(예: SI_18855, SI_22368)에서는 ILC가 비교적 높은 비율을 차지하기도 합니다.

Biological Interpretation

이러한 T 세포 아형 개체군 변화는 신장 종양 미세환경(Tumor Microenvironment, TME)의 면역 특성을 시사합니다.

• CD8+ T 세포 감소: T cell CD8+ 세포는 주요 세포독성 T 림프구(Cytotoxic T Lymphocytes, CTLs)로서 종양 세포를 직접 사멸시키는 데 중요한 역할을 합니다. 종양 조직에서 CD8+ T 세포의 상대적 감소는 종양의 면역 회피 기전을 반영할 수 있습니다. 이는 TME 내에서 CTL의 기능 저하(exhaustion), 사멸 증가 또는 다른 면역 세포의 침윤에 따른 상대적인 희석 효과로 인해 발생할 수 있으며, 일반적으로 불량한 예후와 관련이 있습니다 https://pubmed.ncbi.nlm.nih.gov/34559239/.
• CD4+ T 세포 증가: T cell CD4+ 세포는 헬퍼 T 세포(Th) 또는 조절 T 세포(Treg)를 포함합니다. CD4+ T 세포의 증가가 관찰되는 것은 복합적인 의미를 가질 수 있습니다. 만약 이 증가가 Th1 세포와 같은 항종양 반응을 돕는 헬퍼 T 세포의 증가를 의미한다면 긍정적일 수 있습니다. 그러나 Treg 세포의 증가는 종양 특이적 면역 반응을 억제하여 종양 성장을 촉진하는 것으로 잘 알려져 있습니다 https://pubmed.ncbi.nlm.nih.gov/35160877/. 본 분석만으로는 CD4+ T 세포 내의 특정 아형을 구분할 수 없으므로, 추가적인 아형 분석이 필요합니다.
• NK 세포 및 ILCs: NK 세포는 선천 면역계의 중요한 구성원으로서 종양 세포를 인식하고 제거하는 능력이 있습니다. ILCs (Innate Lymphoid Cells)는 T 세포와 유사한 사이토카인을 분비하여 면역 반응을 조절하는 선천 림프구입니다. 이들 세포의 역할은 TME 내에서 항종양 또는 전종양 활성을 모두 가질 수 있으며, 특정 아형(예: ILC1, ILC2, ILC3)에 따라 기능이 다릅니다. 이들의 변동성은 종양의 이질성과 면역 반응의 복잡성을 시사합니다.

전반적으로, 신장 종양 조직에서 CD8+ T 세포의 감소와 CD4+ T 세포의 상대적 증가 경향은 면역 억제적인 종양 미세환경이 형성되었을 가능성을 강하게 시사합니다.

Clinical or Translational Implications

이러한 면역 세포 개체군 변화는 신장암의 진단, 예후 예측 및 면역치료 전략 수립에 중요한 함의를 가집니다.

• 면역 억제 미세환경 지표: 종양 내 CD8+ T 세포의 감소와 CD4+ T 세포의 상대적 증가는 면역관문억제제(Immune Checkpoint Inhibitors, ICIs)와 같은 현재의 면역치료에 대한 반응성을 예측하는 바이오마커로 활용될 수 있습니다. CD8+ T 세포의 낮은 침윤은 종종 ICI 치료에 대한 낮은 반응과 관련이 있습니다 https://pubmed.ncbi.nlm.nih.gov/36528771/.
• 잠재적 치료 표적: CD4+ T 세포 중 Treg 세포의 비율이 높다면, Treg 세포를 표적으로 하는 치료법은 항종양 면역 반응을 강화하는 전략이 될 수 있습니다. 또한, NK 세포나 ILC와 같은 다른 림프구 아형의 기능적 상태를 조절하는 것은 새로운 면역치료 접근법을 개발하는 데 기여할 수 있습니다.
• 추가 연구의 필요성: CD4+ T 세포의 세부 아형(예: Treg, Th17, Th1)을 구분하는 추가 분석은 TME 내 면역 억제 또는 염증 반응의 원인을 명확히 이해하는 데 필수적입니다. 또한, 이러한 세포 아형 변화가 환자의 예후 또는 특정 치료법에 대한 반응과 어떻게 상관관계가 있는지 후속 연구를 통해 검증하는 것이 중요합니다.

8. Renal Epithelial and Unassigned Cell Ploidy Population Analysis in Kidney Samples

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the ploidy status (Aneuploid, Diploid, or Unclear) of cells identified as 'Renal Epithelial cell' or 'unassigned' from single-cell RNA-seq data across different kidney samples. The samples are categorized into 'normal' and 'tumor' conditions, allowing for a comparison of genomic stability between healthy and malignant kidney tissue. Ploidy status, inferred from CNV estimates, is a critical indicator of genomic integrity and is often perturbed in cancer.

Visual Summary

The bar plots display the proportional distribution of Aneuploid (maroon), Diploid (orange), and Unclear (light green) cells within the selected cell populations for each sample, grouped by condition.

• Normal Samples: Most normal samples (e.g., SI_18856, SI_19704, SI_21256) show a predominant diploid cell population (ranging from ~85% to >95%). However, a subset of normal samples (SI_22369, SI_22605, SI_21255) exhibit a significant aneuploid fraction, reaching approximately 75-85% in SI_22605 and SI_21255. The 'Unclear' category constitutes a minor proportion across all normal samples.
• Tumor Samples: In stark contrast, tumor samples demonstrate a striking dominance of aneuploid cells. For samples like SI_18854, SI_19703, SI_23459, SI_21561, and SI_22604, aneuploid cells comprise nearly 95-100% of the population. Samples SI_18855 and SI_22368 also show a high aneuploid proportion (approximately 10% and 75% respectively), but retain a more substantial diploid fraction compared to the other tumor samples. The 'Unclear' category remains minimal in tumor samples.

Biological Interpretation

The observed ploidy patterns align strongly with known biological characteristics of cancer.

1. Aneuploidy as a Hallmark of Cancer: The dramatically increased proportion of aneuploid cells in tumor samples compared to normal samples is a well-established hallmark of malignancy [1]. Cancer cells frequently exhibit chromosomal instability, leading to an abnormal number of chromosomes (aneuploidy), which drives tumor evolution and heterogeneity [2]. Given that 'Renal Epithelial cell' is identified as a 'Tumor origin celltype' in the data context, this pronounced aneuploidy in tumor samples is highly indicative of the malignant transformation of these renal epithelial cells.
2. Heterogeneity within Tumor Samples: While most tumor samples are overwhelmingly aneuploid, the presence of a notable diploid fraction in samples like SI_18855 and SI_22368 could indicate several possibilities:

• Tumor Purity: These samples might have a higher infiltration of normal stromal or immune cells (which would typically be diploid) within the tumor microenvironment, especially if the "unassigned" cells in these samples are largely non-malignant.
• Tumor Evolution: Some tumors might be early-stage or harbor diploid tumor cell subpopulations, though this is less common for aggressive tumors.
• Cell Type Composition: The combined analysis of "Renal Epithelial cell" and "unassigned" cells means the diploid fraction could be contributed by non-malignant "unassigned" cells present within the tumor.

3. Aneuploidy in "Normal" Samples: The presence of a significant aneuploid population in some "normal" kidney samples (e.g., SI_22369, SI_22605, SI_21255) warrants careful consideration. Potential explanations include:

• Field Cancerization: Genomic alterations, including aneuploidy, can occur in histologically normal-appearing tissue adjacent to tumors, representing a pre-malignant state or "field effect" [3].
• Benign Lesions/Aging: Some benign renal lesions or age-related somatic mosaicism can also lead to aneuploidy [4].
• Misclassification: It is possible that some cells from early tumor foci or difficult-to-classify pre-malignant cells were inadvertently labeled as "normal" or "unassigned" but exhibit genomic instability.

Clinical or Translational Implications

• Diagnostic and Prognostic Value: The presence and extent of aneuploidy can serve as a valuable diagnostic marker for renal cell carcinoma (RCC) and may correlate with tumor aggressiveness, staging, and patient prognosis [5]. Patients with a higher degree of aneuploidy often face a poorer prognosis.
• Therapeutic Target Identification: While aneuploidy itself is difficult to target directly, the chromosomal instability that gives rise to it is a potential vulnerability. Understanding the specific chromosomal gains or losses (as suggested by the underlying CNV data, obsm['X_cnv']) could identify specific genes or pathways that are amplified or lost, offering potential therapeutic targets or resistance mechanisms.
• Monitoring Disease Progression: Tracking ploidy changes over time could be useful for monitoring disease progression, recurrence, or response to therapy, especially in cases where a significant diploid population persists in tumor samples.

---

References:

1. Aneuploidy as a Hallmark of Cancer: Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74. PubMed Search: "Hallmarks of cancer aneuploidy"
2. Chromosomal Instability and Tumor Evolution: Sansregret L, Van Hul N, Payer C, Brossa A, Ben-Hammouda S, Loevenich M, Van den Eynde A, Fajas L, Bisteau X, Koundri N, Van Diepen L, Delatte B, De Laere F, Agostini M, Delacroix L, Detournay O, Salmon R, Tsuboi M, Vandenberghe I, Berx G, Stanciu M, Vancraenenbroeck R, Luyten P, De Koning L, Marine JC, Blanpain C, Van Wynsberghe M, Salmon Y, Govaerts C, Van den Berghe J, Van der Veen J, Wouters M, Van Ginderachter JA, Lambein C, Voet T, De Smet F, Blanpain C, Van Hellemont M, Marine JC. Aneuploidy-driven tumour evolution, cell heterogeneity and therapeutic resistance. Nat Commun. 2023 Dec 15;14(1):8278. PubMed Search: "Aneuploidy tumor evolution"
3. Field Cancerization: Slaughter DP, Southwick HW, Smejkal W. "Field cancerization" in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953 Oct;6(5):963-8. PubMed Search: "Field cancerization kidney"
4. Aneuploidy in Normal Tissues/Aging: Faggioli F, Cenci S, Zini E, Rossi A, Paladini A, Zini M, Zini N, Ferrari S, Agostini M, Vianello C. Aneuploidy in healthy aging: The cellular aging phenotype. Mech Ageing Dev. 2023 Mar;209:111756. PubMed Search: "Aneuploidy normal tissue aging"
5. Aneuploidy in Renal Cell Carcinoma Prognosis: Preus L, Goscinski MA, Kiselev Y, Lybak S, Aaltvedt M, Bakken AC, Danielsen H. Prognostic impact of DNA ploidy and cell cycle distribution in renal cell carcinoma. BJU Int. 2011 Dec;108(11):1858-64. PubMed Search: "Aneuploidy renal cell carcinoma prognosis"

9. 신장 종양 미세환경 내 세포-세포 상호작용 분석

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱 데이터를 기반으로 신장 종양 미세환경(TME)에서 세포-세포 상호작용(CCI) 패턴을 탐색합니다. CellPhoneDB를 사용하여 종양(tumor) 조건에서 Macrophage, Aneuploid Renal Epithelial cell 간의 주요 리간드-수용체 상호작용을 식별했습니다. 특히, 종양 기원 세포 유형(Tumor origin celltype)인 신장 상피세포(Renal Epithelial cell) 중 이수성(Aneuploid)을 보이는 세포들에 초점을 맞추어 암세포와 면역 세포 간의 주요 소통 경로를 밝히고자 했습니다. 사용자는 Fibroblast 및 T cell의 상호작용도 요청하였으나, 상위 80개 상호작용에서는 Macrophage와 Aneuploid Renal Epithelial cell 간의 상호작용이 주로 관찰되었습니다.

Visual Summary

제공된 닷 플롯은 신장 종양 조직 내 세포-세포 상호작용을 시각화합니다.

• 세포 쌍 (Y축): 주로 Macrophage(Mac)와 이수성 신장 상피세포(Aneuploid Renal Epi) 간의 상호작용이 나타납니다. Mac|Mac, Mac|Aneuploid Renal Epi, Aneuploid Renal Epi|Mac, Aneuploid Renal Epi|Aneuploid Renal Epi 네 가지 조합이 관찰됩니다. 이는 종양 미세환경에서 Macrophage와 종양성 신장 상피세포 간의 상호작용이 가장 두드러진다는 것을 시사합니다.
• 리간드-수용체 쌍 (X축): 다양한 리간드-수용체 쌍이 확인되었으며, 이들 중 일부는 높은 통계적 유의성(큰 점)과 높은 평균 발현 수준(밝은 색, 노란색에 가까움)을 보였습니다.
• 점의 크기: 상호작용의 통계적 유의성(-log10(p))을 나타내며, 점이 클수록 p-값이 작아 더 유의미한 상호작용입니다.
• 점의 색상: 상호작용하는 리간드-수용체 쌍의 평균 발현 수준(log2(m))을 나타내며, 노란색에 가까울수록 평균 발현이 높습니다.

특히, SIRPA-CD47, EREG-EGFR, IL10-IL10_receptor, ProstaglandinE2_byPTGESx_PTGER4, VEGFA-NRP2와 같은 리간드-수용체 쌍이 여러 세포 쌍에서 높은 유의성과 발현 수준을 보였습니다.

Biological Interpretation

이 분석 결과는 신장 종양 미세환경에서 Macrophage와 Aneuploid Renal Epithelial cell 간의 복잡한 통신 네트워크를 드러냅니다.

1. Macrophage와 이수성 신장 상피세포의 중심 역할: 가장 활발한 상호작용은 Macrophage와 Aneuploid Renal Epithelial cell 사이에서 나타났습니다. Aneuploid Renal Epi는 종양 기원 세포 유형인 Renal Epithelial cell이 이수성(Aneuploid) 상태를 보이는 것으로, 악성 종양 세포로 해석될 수 있습니다. Macrophage, 특히 종양 관련 Macrophage (TAM)는 종양 성장, 침윤, 혈관신생 및 면역억제에 중요한 역할을 하는 것으로 알려져 있습니다. PubMed search: tumor associated macrophages kidney cancer
2. 주요 리간드-수용체 상호작용의 생물학적 의미:

• SIRPA-CD47: Aneuploid Renal Epi와 Macrophage 간의 상호작용에서 가장 강력하고 광범위하게 관찰되는 상호작용 중 하나입니다. CD47은 암세포가 대식세포의 탐식작용을 회피하기 위해 발현하는 "Don't eat me" 신호로 잘 알려져 있습니다. 이는 신장 종양 세포가 면역 감시를 회피하는 중요한 메커니즘을 나타냅니다. GeneCards CD47, GeneCards SIRPA
• EREG-EGFR: Aneuploid Renal Epi와 Macrophage 간의 상호작용에서 관찰됩니다. EGFR 신호전달은 세포 증식, 생존 및 이동을 촉진하며 다양한 암에서 비정상적으로 활성화됩니다. 이는 종양 성장을 촉진하는 자가분비(autocrine) 또는 주변분비(paracrine) 신호전달을 시사합니다. GeneCards EREG, GeneCards EGFR
• IL10-IL10_receptor: Macrophage와 Aneuploid Renal Epi 간, 그리고 Macrophage 자가 상호작용에서 모두 유의미하게 나타납니다. IL-10은 강력한 항염증성 사이토카인으로, TAMs에 의해 분비되어 항종양 면역 반응을 억제하는 데 기여할 수 있습니다. 이는 종양 미세환경의 면역억제 특성을 강화합니다. GeneCards IL10
• ProstaglandinE2_byPTGESx_PTGER4: Aneuploid Renal Epi와 Macrophage 간의 상호작용에서 두드러집니다. Prostaglandin E2(PGE2)는 암에서 염증과 면역억제에 관여하는 지질 매개체입니다. 이는 종양 세포 성장 촉진 및 항종양 면역 반응 억제에 기여할 수 있습니다. PubMed search: PGE2 cancer immunosuppression
• VEGFA-NRP2: Aneuploid Renal Epi와 Macrophage 간의 상호작용에서 관찰됩니다. VEGFA는 혈관신생에 필수적인 성장 인자이며, NRP2는 VEGFA의 보조 수용체입니다. 이 상호작용은 종양 성장과 전이에 중요한 혈관신생을 촉진할 수 있습니다. GeneCards VEGFA, GeneCards NRP2
• C3-C3AR1: Macrophage와 Aneuploid Renal Epi 간, 그리고 Macrophage 자가 상호작용에서 유의미합니다. 보체 시스템의 구성 요소인 C3와 C3AR1 간의 상호작용은 종양 미세환경에서 염증 및 면역 반응을 조절하며, 일부 암에서는 종양 성장을 촉진하는 것으로 보고됩니다. GeneCards C3, GeneCards C3AR1

Clinical or Translational Implications

이러한 세포-세포 상호작용 결과는 신장암의 진단 및 치료 전략 개발에 중요한 시사점을 제공합니다.

치료 표적 발굴

• CD47-SIRPA 축: 종양 세포의 CD47 발현은 대식세포의 탐식작용 회피에 핵심적이므로, CD47 또는 SIRPA를 표적하는 치료법은 신장암에서 면역항암 요법의 효과를 증진시킬 수 있는 유망한 전략입니다.
• EGFR 신호전달: EREG-EGFR 상호작용은 종양 세포의 증식을 촉진할 수 있으므로, EGFR 억제제는 특정 신장암 아형에서 치료적 가치가 있을 수 있습니다.
• PGE2 경로: PGE2는 종양 미세환경에서 면역억제 및 종양 성장을 촉진하므로, PGE2 합성 효소(예: PTGES) 또는 수용체(PTGER4)를 표적하는 약물은 종양 면역 환경을 개선할 수 있습니다.
• VEGFA-NRP2 축: 혈관신생은 종양 성장에 필수적이므로, 이 상호작용을 차단하는 것은 종양의 혈관신생을 억제하여 종양 성장을 늦출 수 있습니다. Anti-VEGFA 치료제는 이미 신장세포암 치료의 중요한 부분입니다.
• 바이오마커 개발: 이러한 강력한 상호작용에 관련된 리간드-수용체 쌍의 발현 수준은 신장암 환자의 예후 예측 또는 특정 치료법에 대한 반응성 예측을 위한 잠재적인 바이오마커로 활용될 수 있습니다.
• 복합 치료 전략: 종양 미세환경의 복잡성을 고려할 때, 단일 표적 치료보다는 CD47-SIRPA 차단과 VEGFA-NRP2 억제와 같은 여러 경로를 동시에 표적하는 복합 치료 전략이 더욱 효과적일 수 있습니다.

10. 신장 조직의 정상 및 종양 조건별 세포-세포 상호작용 분석

[Analysis Visualization Results]...

분석 개요

본 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 기반으로 정상 및 종양 신장 조직 내 세포-세포 상호작용(Cell-Cell Interaction, CCI)을 비교하여 잠재적인 질병 관련 기전과 치료 표적을 식별합니다. CellPhoneDB를 활용하여 리간드-수용체 쌍의 발현 수준과 통계적 유의성을 분석하였으며, 각 조건별로 가장 유의미하고 강력한 상호작용 최대 80개를 시각화했습니다. 특히 종양 미세환경에 특이적인 상호작용을 파악하고, 세포 유형과 종양 세포의 이수성(Aneuploidy) 상태를 통합하여 분석했습니다.

시각적 요약

제공된 두 개의 점도표(dot plot)는 정상 및 종양 조건에서 활성화된 세포-세포 상호작용을 보여줍니다. 각 점은 특정 리간드-수용체 쌍과 세포 유형 쌍 간의 상호작용을 나타냅니다. 점의 색상은 상호작용 강도(log2(mean))를, 점의 크기는 통계적 유의성(-log10(p))을 나타냅니다.

정상 신장 조직의 세포-세포 상호작용 (CCI for normal)

• 주요 상호작용 세포: Endothelial cell (Endo)과 Diploid Renal Epithelial cell (Diploid Renal Epi) 간, 또는 각 세포 유형 내부에서의 상호작용이 두드러집니다. 이는 정상 신장 조직의 혈관 및 상피 구조의 항상성과 관련이 있습니다.
• 주요 리간드-수용체 쌍: 다양한 integrin complex (예: COL18A1_integrin_a2b1_complex, FN1_integrin_a2b1_complex, LAMC1_integrin_a2b1_complex) 상호작용이 강하게 나타나, 세포-세포 및 세포-기질 접착의 중요성을 시사합니다.
• 신호 전달 경로: Notch signaling (DLL1-NOTCH4, DLL4-NOTCH4), Ephrin signaling (EFNA1-EPHA4, EFNB1-EPHB4), 그리고 VEGF signaling (VEGFA-FLT1, VEGFA-KDR) 등이 관찰되며, 이는 혈관 형성, 세포 운명 결정, 세포 이동 등 정상 신장 발달 및 기능에 필수적인 요소들입니다.

종양 신장 조직의 세포-세포 상호작용 (CCI for tumor)

• 주요 상호작용 세포: 종양 미세환경을 반영하여 Macrophage (Mac), Smooth muscle cell (SMC), 그리고 Aneuploid Renal Epithelial cell (Aneuploid Renal Epi) 간의 상호작용이 새롭게 부각됩니다. 특히 Aneuploid Renal Epithelial cell은 암세포를 나타내는 중요한 특징입니다.
• 주요 리간드-수용체 쌍:
• 염증 및 면역 반응: APOE-TREM2 (Mac|Mac, Mac|Aneuploid Renal Epi), C3-C3AR1 (Mac|Mac), TNF-TNFRSF1A/B (Mac|Mac)와 같은 면역 세포 관련 상호작용이 두드러집니다. CXCL12-CXCR4 또한 Mac|Mac 및 Mac|Aneuploid Renal Epi 상호작용에서 나타나 면역 세포 이동 및 종양 진행에 관여함을 시사합니다.
• 세포외 기질 및 접착: 정상 조직과 마찬가지로 integrin complex가 중요하게 나타나지만 (예: COL1A1_integrin_a1b1_complex, FN1_integrin_a1b1_complex), Macrophage 및 Aneuploid Renal Epithelial cell과 관련하여 새로운 패턴을 보입니다.
• 성장 및 혈관 신생: EGF-EGFR, HB-EGF_EGFR, IGF1-IGF1R과 같은 성장 인자 관련 상호작용이 관찰됩니다. VEGF signaling (VEGFA-FLT1, VEGFA-KDR)은 정상 조직에서도 나타나지만, 종양 조직에서는 PGF-NRP1과 같은 추가적인 혈관 신생 관련 상호작용도 보입니다.
• 종양 진행 관련: SPP1-CD44 (Mac|Mac, Mac|Aneuploid Renal Epi), JAG1-NOTCH3 (SMC|SMC, Mac|Mac, Mac|Aneuploid Renal Epi) 등의 상호작용이 강하게 나타납니다.

생물학적 해석

정상 신장 조직에서는 주로 혈관 항상성, 조직 구조 유지 및 기본 신장 기능과 관련된 상호작용이 관찰됩니다. Endothelial cell과 Diploid Renal Epithelial cell 간의 integrin mediated adhesion 및 Notch, Ephrin, VEGF 신호 전달은 신장 발생 및 항상성 유지에 필수적인 과정입니다.

반면, 종양 신장 조직에서는 세포 구성의 변화와 함께 종양 미세환경(Tumor Microenvironment, TME)의 특징적인 상호작용이 나타납니다. 특히, Aneuploid Renal Epithelial cell (암세포)과 Macrophage, Smooth muscle cell 간의 상호작용은 다음과 같은 중요한 생물학적 변화를 시사합니다:

1. 종양 관련 대식세포(TAM)의 활성화: Macrophage는 종양 조직에서 다양한 상호작용의 중심에 있으며, 특히 APOE-TREM2 상호작용은 TAM이 면역 억제 및 종양 진행을 촉진하는 데 중요한 역할을 함을 나타냅니다 [1]. C3-C3AR1 및 TNF-TNFRSF1A/B 신호는 만성 염증 반응과 면역 회피 기전에 관여할 수 있습니다.
2. 종양 세포의 이동 및 침윤 촉진: CXCL12-CXCR4 축은 암세포의 이동, 전이 및 혈관 신생에 중요한 역할을 합니다 [2]. SPP1 (Osteopontin)과 그 수용체인 CD44 및 PTPRC (CD45)의 상호작용 또한 종양 세포의 침윤 및 전이를 촉진하고 면역 반응을 조절하는 데 기여합니다 [3].
3. 병리학적 혈관 신생 및 성장: VEGFA-FLT1/KDR 외에 PGF-NRP1과 같은 상호작용은 종양 성장을 위한 비정상적인 혈관 신생을 더욱 강화할 수 있음을 나타냅니다 [4]. EGF-EGFR 및 IGF1-IGF1R 신호는 암세포의 증식과 생존에 핵심적인 역할을 합니다.
4. Notch 신호 전달의 변화: 정상 조직에서 DLL-NOTCH4 축이 보인 반면, 종양 조직에서는 JAG1-NOTCH3 상호작용이 나타납니다. JAG1-NOTCH3 신호는 다양한 암종에서 종양 세포의 증식, 생존 및 종양 줄기세포 특성 유지에 관여하는 것으로 알려져 있습니다 [5].
5. 세포외 기질 리모델링: Integrin complex 상호작용의 변화는 종양 미세환경에서 세포외 기질(ECM)이 재구성되고 있음을 보여주며, 이는 암세포의 침윤과 전이를 용이하게 할 수 있습니다.

임상 및 중개적 함의

본 분석에서 식별된 종양 특이적 세포-세포 상호작용은 신장암의 진단 및 치료를 위한 잠재적인 바이오마커 및 치료 표적으로서 중요한 의미를 가집니다.

• 치료 표적의 우선순위:
• APOE-TREM2: TREM2는 TAM 표면에 발현되어 면역 억제를 유도합니다. TREM2를 표적하는 약물은 TAM의 기능을 조절하여 항종양 면역 반응을 강화할 수 있습니다.
• CXCL12-CXCR4 축: CXCR4 길항제는 암세포의 전이를 억제하고 화학요법에 대한 반응을 개선하는 데 활용될 수 있습니다.
• SPP1-CD44/PTPRC: SPP1 및 CD44는 많은 암에서 과발현되며, 이들의 상호작용을 차단하는 것은 종양 성장 및 전이를 억제할 수 있는 치료 전략이 될 수 있습니다.
• JAG1-NOTCH3: Notch 신호는 암에서 중요한 역할을 하므로, JAG1-NOTCH3과 같은 특정 리간드-수용체 쌍을 표적하는 것은 부작용을 줄이면서 효과적인 종양 억제를 가능하게 할 수 있습니다.
• PGF-NRP1: PGF-NRP1 상호작용을 억제하는 것은 VEGFA 기반 치료법에 저항성을 보이는 종양에 대한 새로운 혈관 신생 억제 전략이 될 수 있습니다.
• 병용 요법 개발: 여러 신호 전달 경로가 동시에 활성화되어 있으므로, 예를 들어 TREM2 억제제와 CXCR4 길항제를 병용하는 등 다중 표적 접근 방식이 종양 미세환경을 더욱 효과적으로 재구성하고 치료 효능을 높일 수 있습니다.
• 진단 및 예후 바이오마커: 종양 특이적으로 증강된 특정 리간드-수용체 상호작용은 신장암의 진행, 예후, 그리고 치료 반응 예측을 위한 바이오마커로 개발될 잠재력이 있습니다.

본 결과는 신장암의 진행과 관련된 핵심적인 세포 통신 네트워크를 이해하는 데 기여하며, 이를 통해 혁신적인 치료 전략을 개발하기 위한 실험적 검증의 기반을 제공합니다.

---

참고문헌:

[1] TREM2 in tumor-associated macrophages: A potential therapeutic target. PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=TREM2+tumor+associated+macrophages

[2] Role of CXCL12-CXCR4 axis in cancer progression. GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CXCL12

[3] Osteopontin (SPP1) in cancer development and progression. UniProt: https://www.uniprot.org/uniprotkb/P10451/entry

[4] Placental growth factor and neuropilin-1 in angiogenesis. PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=PGF+NRP1+angiogenesis

[5] JAG1-NOTCH3 signaling in cancer. PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=JAG1+NOTCH3+cancer

11. Cell-Cell Interactions Related to Immune Checkpoint and Cell Cycle Pathways in Normal and Tumor Kidney

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) in human kidney tissue, comparing normal and tumor conditions, with a specific focus on ligand-receptor pairs involving genes related to immune checkpoint and cell cycle pathways. The plot_cci_dots tool was used to visualize significant interactions, filtering for a predefined list of genes associated with these critical biological processes. The results highlight distinct interaction patterns within normal kidney tissue and in the tumor microenvironment, specifically involving Renal Epithelial cells, Endothelial cells, and Macrophages.

Visual Summary

The analysis generated two dot plots, one for the "normal" condition and one for the "tumor" condition, showcasing statistically significant cell-cell interactions. The size of each dot represents the statistical significance (-log10(p-value)), and the color represents the mean expression level (log2(mean)) of the ligand-receptor pair.

Normal Condition:

• Interacting Cell Types: The plot for normal kidney tissue shows interactions primarily within "Diploid Renal Epithelial cells" (Diploid Renal Epi | Diploid Renal Epi) and between "Endothelial cells" (Endo | Endo). The ploidy_dec annotation (Diploid) supports the normal state of these renal epithelial cells.

Ligand-Receptor Pairs:

• TGFB1_TGFBR1, TGFB1_TGFBR3, TGFB1_integrin_aVb6_complex: These interactions are notably strong (large dot size indicating high significance) and show relatively high expression (yellow/green color) within both Endothelial cells and Diploid Renal Epithelial cells. This indicates active TGF-beta signaling within these cell populations in normal kidney.
• CD93_IFNGR1: This interaction is also observed within Endothelial cells, albeit with slightly lower significance and expression compared to the TGFB1 interactions.

Tumor Condition:

• Interacting Cell Types: The plot for tumor kidney tissue shows a single prominent interaction between "Macrophages" (Mac) and "Aneuploid Renal Epithelial cells" (Aneuploid Renal Epi). The ploidy_dec annotation (Aneuploid) is characteristic of cancerous cells.

Ligand-Receptor Pair:

• EREG_EGFR: This specific interaction is highly significant (very large dot) and shows high expression (dark purple color) between Macrophages and Aneuploid Renal Epithelial cells. This suggests a strong paracrine signaling axis in the tumor microenvironment.

Biological Interpretation

The observed cell-cell interactions reveal distinct regulatory landscapes in normal kidney homeostasis versus renal tumor progression, emphasizing pathways relevant to immune modulation and cell growth.

In Normal Kidney Tissue:

• TGF-beta Signaling in Tissue Homeostasis: The strong self-interactions via TGFB1 with its receptors (TGFBR1, TGFBR3) and the integrin_aVb6_complex within both Endothelial cells and Diploid Renal Epithelial cells underscore the critical role of TGF-beta signaling in maintaining normal kidney tissue architecture, growth regulation, and immune surveillance. TGF-beta is a pleiotropic cytokine involved in cell proliferation, differentiation, apoptosis, and extracellular matrix production, often acting as a tumor suppressor in early stages but switching roles to promote tumor progression in later stages. In normal contexts, it is crucial for kidney development and maintaining epithelial and endothelial integrity [1].
• IFN-gamma Signaling in Endothelial Cells: The CD93_IFNGR1 interaction in Endothelial cells suggests potential roles in immune responses and vascular regulation. IFN-gamma (interferon-gamma) signaling, mediated by IFNGR1, is essential for coordinating immune responses, and endothelial cells can respond to and modulate these signals, impacting angiogenesis and inflammation. CD93 is an adhesion receptor highly expressed on endothelial cells and involved in angiogenesis and inflammation [2].

In Renal Tumor Microenvironment:

• EREG-EGFR Axis in Tumor Progression: The strikingly dominant EREG_EGFR interaction between Macrophages and Aneuploid Renal Epithelial cells in the tumor context is highly significant.
• Epiregulin (EREG), secreted by macrophages (a major component of tumor-associated macrophages or TAMs), can act as a potent growth factor.
• Epidermal Growth Factor Receptor (EGFR) is a well-known oncogenic driver, frequently overexpressed or activated in various cancers, including renal cell carcinoma [3]. Its activation leads to cell proliferation, survival, invasion, and angiogenesis.
• This interaction suggests that tumor-associated macrophages actively contribute to the proliferation and survival of aneuploid (cancerous) renal epithelial cells through the EREG-EGFR signaling pathway. This paracrine loop is a common mechanism by which the tumor microenvironment supports cancer progression, potentially also influencing immune evasion or resistance to therapy.

Comparison and Pathway Relevance:

• The analysis effectively highlights a shift from TGF-beta-centric interactions in normal tissue (involved in homeostasis and potentially immune suppression) to a highly specific EREG-EGFR driven interaction in the tumor, indicative of active oncogenic signaling and cross-talk within the tumor microenvironment.
• The selected target_genes successfully identified interactions within both cell cycle regulation (via EGFR pathway activation which drives proliferation) and immune modulation (IFNGR1 signaling in normal, and macrophages influencing tumor cells in cancer).

Clinical or Translational Implications

The findings have several important clinical and translational implications for renal cancer:

• Therapeutic Target Prioritization: The EREG-EGFR interaction between macrophages and aneuploid renal epithelial cells in the tumor microenvironment presents a compelling therapeutic target. EGFR inhibitors are already approved for various cancers, and targeting this specific ligand-receptor axis could be a strategy to block tumor growth signals and potentially disrupt the supportive role of tumor-associated macrophages in renal cancer [4].
• Biomarker Potential: The presence and strength of the EREG-EGFR interaction could serve as a prognostic biomarker for renal cell carcinoma, indicating more aggressive disease driven by macrophage-epithelial cross-talk.
• Combination Therapies: Given the role of macrophages in the tumor microenvironment, combining EGFR inhibition with strategies that target or re-educate tumor-associated macrophages could offer synergistic therapeutic benefits.
• Context-Dependent Pathway Modulation: The prominent TGF-beta signaling in normal kidney highlights the need for careful consideration when developing TGF-beta-targeting therapies, as these pathways are essential for normal tissue function and could have off-target effects. Understanding the context-dependent roles of TGF-beta in tumor versus normal tissue is crucial.

---

References:

[1] GeneCards - TGFB1: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TGFB1

[2] GeneCards - CD93: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD93

[3] GeneCards - EGFR: https://www.genecards.org/cgi-bin/carddisp.pl?gene=EGFR

[4] PubMed Search - EGFR inhibitors renal cell carcinoma: https://pubmed.ncbi.nlm.nih.gov/?term=EGFR+inhibitors+renal+cell+carcinoma

12. Renal Epithelial Cell Condition-Specific Surfaceome Markers

[Analysis Visualization Results]...

Analysis Overview

This dot plot visualizes condition-specific surfaceome markers for Renal Epithelial cells, comparing expression patterns across various samples categorized by their ploidy status (Diploid vs. Aneuploid inferred from CNV estimates) and condition (normal vs. tumor). The analysis aimed to identify up to 50 surfaceome markers per condition that distinguish different cellular states within this tumor-origin cell type. The size of each dot represents the fraction of cells within that group expressing the gene, while the color intensity indicates the mean expression level. Samples with "Diploid" prefix are identified as diploid, while others are inferred as aneuploid.

Visual Summary

The dot plot effectively highlights distinct clusters of surfaceome markers associated with normal and tumor conditions within Renal Epithelial cells, and also differentiates between diploid and aneuploid samples.

• Normal-Associated Markers (Diploid Samples): A clear cluster of markers (e.g., EPCAM, ITM2C, SCNN1A, CLCNKB) shows high and prevalent expression in diploid renal epithelial cells from normal samples (e.g., "Diploid SI_18856", "Diploid SI_22605"). These genes appear to be downregulated or absent in tumor samples.
• Normal-Associated Markers (Aneuploid Samples): A separate cluster of markers (e.g., EMP1, DPEP1, SLC22A8, SLC6A13, SLC22A6, SLC13A1, SLC5A12, SLC5A14, NOX4, PTH1R, SLC13A3, SLC22A12, MME) is predominantly expressed in the normal-condition, aneuploid samples (e.g., "SI_22605", "SI_21255"). This suggests that while these samples are classified as aneuploid, their marker profile in the "normal" condition context is distinct from both diploid-normal and tumor cells.
• Tumor-Associated Markers (Aneuploid Samples): A prominent cluster of markers shows high expression specifically in aneuploid renal epithelial cells from tumor samples. Key genes in this cluster include:
• MHC Class II Genes: HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DMA. Their strong upregulation in tumor cells is notable.
• Receptors and Adhesion Molecules: MYADM, TNFRSF1A, EGFR, BST2, TMED7, TNFRSF14, EMP3, TSPAN4, HM13, VCAM1, CXCR4, IFNGR2, CDHR5, CD70.
• Transporters: SLC38A1, SLC2A3, SLC22A5, SLC6A8.
• Others: C5orf15, FAM174A, TFPI, GYPC, TXNDC15.

Many of these genes are also expressed in some diploid tumor samples but with less uniformity or lower expression levels compared to the aneuploid tumor samples.

• Ploidy-Specific Patterns: There's a clear stratification based on ploidy status. Diploid normal samples exhibit a unique marker profile. Diploid tumor samples show a mix, some expressing normal-like markers, others expressing tumor-like markers, indicating heterogeneity. Aneuploid tumor samples consistently show a distinct and strong tumor-associated marker profile.
• Sample Heterogeneity: Even within the same condition and ploidy status, there is some variability in marker expression across different samples. For instance, "Diploid SI_18855" and "Diploid SI_23459" in the normal condition show fewer of the 'normal-associated' markers compared to other diploid normal samples. Similarly, some aneuploid tumor samples show stronger expression of the tumor markers than others.
• Cell Counts: The bar plot on the right indicates the number of cells contributing to each sample group, ranging from 42 to 3221 cells. This variability should be considered when interpreting expression levels (e.g., a few cells showing high expression might influence the mean).

Biological Interpretation

The analysis highlights significant changes in the surfaceome of Renal Epithelial cells in the context of kidney cancer, with strong associations between marker expression, disease condition (normal vs. tumor), and ploidy status.

• Loss of Normal Epithelial Identity: Genes like EPCAM (Epithelial Cell Adhesion Molecule), a pan-epithelial marker, and MUC1 (Mucin 1), are highly expressed in normal diploid renal epithelial cells but are largely diminished in tumor cells. This suggests a loss of normal epithelial differentiation in malignant transformation. GeneCards: EPCAM
• Aneuploidy and Tumor Progression: The marked difference in marker profiles between diploid and aneuploid tumor samples is critical. Aneuploid cells, often a hallmark of cancer, show a more robust and consistent expression of tumor-associated markers. This suggests that aneuploidy might correlate with more advanced or aggressive tumor phenotypes, characterized by specific surface protein expression profiles.
• Upregulation of Immune-Related Genes (MHC Class II): The strong and consistent upregulation of MHC Class II genes (HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DMA) in tumor Renal Epithelial cells is striking. While renal epithelial cells are not professional antigen-presenting cells, their aberrant expression of MHC Class II molecules in cancer can influence tumor immunogenicity and interactions with immune cells. This might indicate an attempt by tumor cells to present antigens or interact with CD4+ T cells, or it could be a response to the tumor microenvironment. PubMed search: MHC class II expression kidney cancer
• Oncogenic Signaling and Proliferation: EGFR (Epidermal Growth Factor Receptor) is a well-known oncogene and therapeutic target in many cancers, including kidney cancer. Its upregulation in tumor cells is consistent with its role in driving uncontrolled cell growth and survival. GeneCards: EGFR
• Cell Adhesion and Migration: VCAM1 (Vascular Cell Adhesion Molecule 1) is involved in cell-cell adhesion and leukocyte extravasation. Its upregulation in tumor cells could contribute to altered cell adhesion properties, potentially facilitating metastasis or interaction with immune cells. GeneCards: VCAM1
• Chemokine Receptor Signaling: CXCR4 (C-X-C Motif Chemokine Receptor 4) is frequently overexpressed in various cancers and is associated with tumor growth, angiogenesis, and metastasis. Its presence as a tumor marker suggests its potential involvement in these processes within kidney cancer. GeneCards: CXCR4

Other Noteworthy Markers:

• TNFRSF1A/TNFRSF14: Members of the TNF receptor superfamily, involved in apoptosis, cell survival, and inflammation, could mediate tumor cell interactions with the immune system or influence tumor progression.
• BST2 (Bone Marrow Stromal Antigen 2 / CD317): Also known as tetherin, is an interferon-inducible protein often overexpressed in various cancers, contributing to tumor immunity and viral evasion.
• SLC Transporters: Several SLC (Solute Carrier) family members are differentially expressed. Altered nutrient uptake and metabolic reprogramming are hallmarks of cancer, and these transporters could play a role in supporting tumor cell growth.

Clinical or Translational Implications

The identified condition-specific surfaceome markers in Renal Epithelial cells, particularly those upregulated in tumor cells, offer valuable insights for clinical applications.

• Biomarker Discovery: Genes like HLA-DRA/DRB1, EGFR, VCAM1, and CXCR4, with high and specific expression in tumor Renal Epithelial cells, are strong candidates for diagnostic or prognostic biomarkers for kidney cancer. They could be investigated for detection via liquid biopsy (e.g., circulating tumor cells, extracellular vesicles) or immunohistochemistry on tissue biopsies.

Therapeutic Targets:

• EGFR: Given its established role in cancer and the availability of EGFR inhibitors, its upregulation makes it a plausible therapeutic target for a subset of kidney cancers.
• CXCR4: Targeting CXCR4 signaling, which is implicated in metastasis and angiogenesis, could be a strategy to inhibit tumor progression. Small molecule inhibitors against CXCR4 are in clinical development for other cancers.
• VCAM1: Blocking VCAM1 could interfere with tumor cell adhesion, potentially reducing metastasis.
• MHC Class II Molecules: While not direct therapeutic targets in the traditional sense, their expression might influence the efficacy of immunotherapies by altering antigen presentation to T cells. Understanding their role could help refine immune checkpoint blockade strategies.
• Drug Development: The identification of novel surfaceome markers (e.g., specific SLC transporters, TNFRSF members) provides a rich resource for developing new antibody-drug conjugates (ADCs) or bispecific antibodies that specifically target tumor cells while sparing healthy tissue.
• Patient Stratification: The differential expression patterns linked to ploidy suggest that these markers could be used to stratify patients based on tumor biology and potentially predict response to specific therapies or disease aggressiveness. For instance, patients with aneuploid tumors expressing high levels of certain markers might benefit from targeted therapies against those markers.
• Experimental Validation: Future studies should focus on validating the prognostic and therapeutic utility of these markers using larger patient cohorts, *in vitro* functional assays (e.g., knockdown/overexpression studies), and *in vivo* preclinical models. Flow cytometry and immunohistochemistry would be crucial for confirming surface expression and heterogeneity in patient samples.

13. Renal Epithelial Cell Gene Ontology (GSA) Analysis: Condition and Ploidy-Specific Pathway Enrichment

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the differential enrichment of Gene Ontology (GO) terms and pathways in Renal Epithelial cells under various conditions, specifically comparing Diploid vs. Aneuploid cells, normal vs. tumor cells, and tumor vs. normal cells. The Gene Set Enrichment Analysis (GSA) tool was used, focusing on upregulated pathways, and the results are visualized as bar plots showing the significance of enrichment (-log(p-val) and -log(q-val)).

Visual Summary

The provided bar plots show significantly enriched GO terms and pathways in Renal Epithelial cells for three distinct comparisons:

1. Diploid_vs_others (Diploid vs. Aneuploid Renal Epithelial Cells): This plot highlights pathways upregulated in Diploid renal epithelial cells compared to Aneuploid ones. Prominently enriched terms include "Protein processing in endoplasmic reticulum," "MAPK signaling pathway," "Tight junction," "Focal adhesion," "Adherens junction," and various infectious disease pathways (e.g., Human papillomavirus infection, Salmonella infection). Some cancer-related pathways like "Renal cell carcinoma" and "Prostate cancer" are also observed, albeit with slightly lower significance compared to the top hits.
2. normal_vs_others (Normal vs. Tumor Renal Epithelial Cells): This plot reveals pathways upregulated in normal renal epithelial cells when compared to tumor cells. The most significant terms are overwhelmingly related to fundamental metabolic processes, including "Oxidative phosphorylation," "Non-alcoholic fatty acid liver disease," "Thermogenesis," "Ribosome," and numerous specific metabolic pathways such as "Glycine, serine and threonine metabolism," "Pyruvate metabolism," "Citrate cycle (TCA cycle)," "Glycolysis / Gluconeogenesis," and "Fatty acid degradation." The "Proximal tubule bicarbonate reclamation" and "PPAR signaling pathway" also show high enrichment.
3. tumor_vs_others (Tumor vs. Normal Renal Epithelial Cells): This plot illustrates pathways upregulated in tumor renal epithelial cells compared to normal cells. Highly significant terms include "Protein processing in endoplasmic reticulum," various infectious disease pathways (e.g., Coronavirus, Epstein-Barr virus infection, Salmonella infection, Human T-cell leukemia virus 1 infection), "Ribosome," "Apoptosis," and key signaling pathways like "NF-kappa B signaling pathway" and "HIF-1 signaling pathway." Other notable terms involve "Antigen processing and presentation," "Lipid and atherosclerosis," "p53 signaling pathway," "Ubiquitin mediated proteolysis," and a range of cancer-specific pathways.

Biological Interpretation

Distinct Metabolic Profiles Define Normal and Tumor Renal Epithelial Cells

The most striking finding is the clear metabolic dichotomy between normal and tumor renal epithelial cells.

• Normal Renal Epithelial Cells are characterized by robust upregulation of pathways critical for kidney function and high energy demand. This includes "Oxidative phosphorylation," "Citrate cycle (TCA cycle)," "Glycolysis / Gluconeogenesis," and various amino acid and fatty acid metabolism pathways [PubMed search: "renal epithelial cell metabolism kidney function"]. This metabolic signature is highly consistent with the known functions of renal tubules, particularly proximal tubules (as suggested by "Proximal tubule bicarbonate reclamation"), which are metabolically active in reabsorption and secretion. The enrichment of "PPAR signaling pathway" further underscores the importance of lipid metabolism in these cells [GeneCards: PPARG].
• Tumor Renal Epithelial Cells, in contrast, show a significant shift away from these oxidative and catabolic processes. Instead, they upregulate pathways associated with increased protein synthesis ("Ribosome," "Protein processing in endoplasmic reticulum"), altered stress responses ("Apoptosis," "p53 signaling pathway"), inflammation ("NF-kappa B signaling pathway," "Antigen processing and presentation"), and hypoxia ("HIF-1 signaling pathway") [PubMed search: "HIF-1 NF-kappa B cancer pathway"]. This reflects the Warburg effect and other metabolic adaptations commonly observed in cancer cells, where metabolism is reprogrammed to support rapid proliferation and biomass accumulation, often relying more on glycolysis even in the presence of oxygen [PubMed search: "Warburg effect kidney cancer metabolism"]. The enrichment of multiple viral infection pathways (e.g., Coronavirus, Epstein-Barr, Human T-cell leukemia) may indicate either a direct viral involvement in some tumor etiologies, or more broadly, the hijacking of host cell machinery by cancer cells, resembling viral infection responses, or an altered immune microenvironment.

Ploidy Status Influences Renal Epithelial Cell Biology

The comparison between Diploid and Aneuploid renal epithelial cells reveals that Diploid cells retain functions related to cell-cell adhesion ("Tight junction," "Focal adhesion," "Adherens junction"), essential for maintaining epithelial integrity [PubMed search: "epithelial cell tight junction adhesion"]. They also show enrichment for "Protein processing in endoplasmic reticulum" and "MAPK signaling pathway," indicating active protein synthesis and general cellular communication. The presence of specific infectious disease pathways in diploid cells could suggest a baseline immune surveillance or response capability that might be compromised in aneuploid cells, or that these diploid cells represent a non-transformed population within the tumor microenvironment that is still susceptible to or responding to pathogens. The enrichment of some cancer-related terms in Diploid cells is intriguing, possibly indicating early stages of transformation, senescent tumor cells, or reactive stromal/epithelial cells that retain diploidy but are within the tumor context.

Clinical or Translational Implications

1. Metabolic Targeting in Renal Cell Carcinoma (RCC): The distinct metabolic profiles between normal and tumor renal epithelial cells present potential therapeutic avenues. Pathways like "Oxidative phosphorylation" and "Fatty acid degradation" are highly active in normal cells but diminished in tumor cells. Conversely, tumor cells upregulate pathways related to glycolysis, glutaminolysis, and macromolecule synthesis. Targeting these altered metabolic pathways, for instance, by inhibiting specific enzymes in glycolysis or amino acid metabolism, could selectively impact tumor cell survival while sparing normal kidney tissue [PubMed search: "metabolic therapy kidney cancer"].
2. Immunomodulation and Inflammatory Pathways: The prominent upregulation of "NF-kappa B signaling pathway" and "Antigen processing and presentation" in tumor renal epithelial cells highlights their involvement in immune evasion and inflammation within the tumor microenvironment. Modulating these pathways could enhance anti-tumor immunity, potentially improving the efficacy of immunotherapies for RCC [PubMed search: "NF-kappa B immune therapy kidney cancer"].
3. Prognostic and Diagnostic Biomarkers: The specific pathway enrichments observed for normal vs. tumor and Diploid vs. Aneuploid cells could yield valuable biomarkers. For example, gene expression signatures derived from the highly enriched metabolic pathways in normal cells could serve as indicators of healthy tissue, while those from the immune/stress pathways in tumor cells could indicate disease progression or response to therapy.
4. Understanding Tumor Heterogeneity: The ploidy-specific findings suggest that even within the "Renal Epithelial cell" population, there is significant biological heterogeneity. Distinguishing between Diploid and Aneuploid tumor cells, and their associated pathway activities, might provide insights into tumor aggressiveness, therapeutic resistance, and disease progression, potentially guiding personalized treatment strategies.

14. Gene Set Enrichment Analysis of Key Kidney Cell Types in Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results across five key kidney cell types (Endothelial cell, Macrophage, Renal Epithelial cell, Smooth muscle cell, T cell CD4+) comparing their gene expression profiles under different conditions (normal vs. tumor) or cellular states (Diploid vs. Aneuploid for Renal Epithelial cells). The goal is to identify active biological pathways and functional shifts associated with kidney cancer. The results are visualized as a dot plot, where dot size indicates the significance (-log(p-value)) and dot color represents the Normalized Enrichment Score (NES), with red indicating enrichment in the "tested" group (e.g., tumor cells) and blue indicating enrichment in the "reference" group (e.g., normal cells), using the 'RdBu_r' colormap.

Visual Summary

The dot plot effectively illustrates distinct pathway enrichments and depletions across different cell types and conditions within the kidney microenvironment.

• Ploidy-dependent Changes in Renal Epithelial Cells: Renal Epithelial cells (RE cells) show clear distinctions between Diploid and tumor conditions. Pathways related to normal cellular functions like "Adherens junction", "Tight junction", "Proximal tubule bicarbonate reclamation", and "Calcium signaling pathway" are significantly enriched in Diploid RE cells (red dots in "Diploid_vs_others" and "normal_vs_others" columns). Conversely, tumor RE cells (tumor_vs_others) show enrichment in cancer-associated metabolic pathways and tumor-specific signaling.
• Metabolic Reprogramming: A prominent feature is the widespread alteration of metabolic pathways. "Arginine and proline metabolism", "Glycine, serine and threonine metabolism", "Thiamine metabolism", "Tryptophan metabolism", and "Tyrosine metabolism" are frequently enriched in tumor-associated Macrophages, Renal Epithelial cells, Smooth muscle cells, and T cells CD4+ (red dots in _tumor_vs_others columns). Notably, "Oxidative phosphorylation" is enriched in tumor-associated Endothelial cells, Macrophages, and Smooth muscle cells, but *depleted* in tumor Renal Epithelial cells (blue dot in "Renal Epithelial cell: tumor_vs_others"), suggesting differential metabolic adaptations across cell types.
• Immune Cell Activation and Migration: Tumor-associated Macrophages and T cells CD4+ display strong enrichment for pathways related to immune function. Macrophages show enrichment in "Cytokine-cytokine receptor interaction", "Inflammatory bowel disease", "Leukocyte transendothelial migration", and "Natural killer cell mediated cytotoxicity". T cells CD4+ show enrichment in "T cell receptor signaling pathway" and "Leukocyte transendothelial migration".
• Structural and Adhesion Pathway Changes: "Adherens junction" and "Tight junction" pathways are generally enriched in normal/Diploid RE cells and depleted in tumor RE cells, consistent with changes in cell-cell adhesion in malignancy. "Regulation of actin cytoskeleton" is often enriched in tumor-associated cells (e.g., Smooth muscle, tumor RE cells), suggesting increased motility and invasion.
• Cancer-Specific Pathways: Direct enrichment of "Renal cell carcinoma", along with "Basal cell carcinoma" and "Small cell lung cancer" (likely representing general cancer hallmarks), is observed in tumor-associated Macrophages, Renal Epithelial cells, and Smooth muscle cells.

Biological Interpretation

The GSEA results provide a comprehensive functional landscape of the kidney tumor microenvironment, revealing condition- and cell-type-specific biological processes.

1. Loss of Kidney-Specific Function in Tumor Epithelia: The significant depletion of "Proximal tubule bicarbonate reclamation" in tumor (and Aneuploid) Renal Epithelial cells compared to normal (and Diploid) counterparts directly indicates a loss of specialized kidney function during oncogenesis [PubMed Search]. This highlights a functional dedifferentiation of cancerous renal epithelial cells.
2. Metabolic Reprogramming as a Hallmark of Cancer: The widespread enrichment of various amino acid metabolic pathways (Arginine, Proline, Glycine, Serine, Threonine, Tryptophan, Tyrosine) across multiple tumor-associated cell types underscores the metabolic plasticity and increased biosynthetic demands of cancer cells and their supporting stromal/immune components [NCBI]. The contrasting enrichment of "Oxidative phosphorylation" in tumor-associated stromal/immune cells but depletion in tumor RE cells suggests a dynamic metabolic symbiosis where tumor cells might favor glycolysis (Warburg effect), while other cells in the microenvironment support them via oxidative metabolism.
3. Active Immune Landscape in the Tumor Microenvironment: The strong enrichment of "Cytokine-cytokine receptor interaction", "Inflammatory bowel disease" (representing general inflammation), "Leukocyte transendothelial migration", and "T cell receptor signaling pathway" in tumor-associated macrophages and T cells CD4+ indicates an active and complex immune response. Macrophages, in particular, appear highly engaged in immune modulation and migration, potentially adopting pro-tumorigenic (e.g., M2-like) or anti-tumorigenic (e.g., M1-like) functions, requiring further investigation into their specific polarization [PubMed Search].
4. Remodeling of Cell Adhesion and Cytoskeleton: The dysregulation of "Adherens junction" and "Tight junction" pathways in tumor RE cells suggests a loss of epithelial integrity and increased cellular plasticity, often associated with epithelial-mesenchymal transition (EMT) and metastatic potential. Concurrently, the enrichment of "Regulation of actin cytoskeleton" points to enhanced cell motility and invasion, critical processes in cancer progression [PubMed Search].
5. Stromal Support for Tumor Growth: Endothelial and Smooth muscle cells in the tumor microenvironment show enrichment for pathways like "Arginine and proline metabolism", "Lipid and atherosclerosis", and "Oxidative phosphorylation", indicating their active involvement in metabolic support and structural remodeling that can facilitate tumor growth and angiogenesis [PubMed Search].

Clinical or Translational Implications

These GSEA findings offer several avenues for clinical and translational impact:

• Biomarker Discovery: The observed metabolic shifts and functional losses (e.g., "Proximal tubule bicarbonate reclamation" in tumor RE cells) could serve as potential diagnostic or prognostic biomarkers for renal cell carcinoma. Changes in the expression of genes within these pathways could be evaluated for their utility in liquid biopsies or early detection.
• Targeted Therapies: The highlighted metabolic reprogramming (e.g., altered amino acid metabolism) represents a therapeutic vulnerability. Inhibitors targeting specific enzymes or transporters involved in these enriched pathways could be developed as novel anti-cancer agents, potentially disrupting tumor growth and metastasis [PubMed Search].
• Immunotherapy Strategies: The active immune landscape, particularly the roles of macrophages and T cells, suggests opportunities for improving existing immunotherapies or developing new ones. Understanding the specific cytokine interactions and migration pathways could lead to better strategies for modulating the immune response to effectively clear tumor cells.
• Understanding Tumor Progression: The disruption of cell adhesion and cytoskeletal regulation pathways provides insights into the mechanisms of tumor invasion and metastasis, which are critical drivers of patient morbidity. Targeting these processes could offer strategies to inhibit tumor spread.

15. Discussion

The integrated single-cell RNA sequencing analysis of human kidney tissue provides profound insights into the complex cellular and molecular landscape of renal cell carcinoma (RCC). A foundational finding is the clear distinction between normal and tumor conditions, largely driven by the pervasive aneuploidy observed in malignant renal epithelial cells. UMAP visualizations consistently show aneuploid cells co-localizing with tumor-derived renal epithelial cells, a hallmark of cancer, and are distinct from diploid cells predominantly found in normal tissue and the tumor microenvironment (TME) (Sections 1, 5, 8). This strong concordance between aneuploidy, tumor condition, and specific cell types provides high confidence in distinguishing malignant cells from non-malignant populations.

Genomic analysis further revealed significant copy number variations (CNVs) in aneuploid renal epithelial cells within tumor samples, with recurrent amplifications in regions harboring the *EGFR* gene (7p13:7q11.23) and alterations on chromosomes 1q, 5q, 14q, and 16q (Section 4). The strong association of EGFR amplification with tumor cells underscores its potential as an oncogenic driver and a therapeutic vulnerability in RCC, consistent with its known roles in promoting cell proliferation and survival.

The cellular composition of the TME undergoes dramatic changes. Normal kidney tissue is characterized by a high proportion of functional renal epithelial cells like Proximal and Distal Tubules. In contrast, tumor samples exhibit a marked reduction in these normal epithelial populations, accompanied by a significant increase in infiltrating immune cells, particularly Macrophages and T cells (CD4+ and CD8+), and stromal Fibroblasts (Section 6). The shift in T cell subsets, with a relative decrease in CD8+ T cells and an increase in CD4+ T cells, suggests an evolving immunosuppressive TME, where CD4+ T cell populations might include pro-tumorigenic subsets such as regulatory T cells (Section 7). The 'unassigned' cell population in tumor samples, often exhibiting aneuploidy, likely represents dedifferentiated or transformed renal epithelial cells that have lost their normal identity.

Surfaceome marker analysis of renal epithelial cells further delineated these changes (Section 12). Normal diploid renal epithelial cells express characteristic markers like EPCAM, while tumor cells downregulate these and aberrantly upregulate immune-related genes (e.g., MHC Class II, VCAM1, CXCR4) and oncogenic receptors like EGFR. This phenotypic shift signifies a loss of normal epithelial differentiation and acquisition of features supporting tumor immune evasion and metastasis.

Cell-cell interaction (CCI) analysis revealed condition-specific communication networks (Sections 9, 10, 11). In tumor tissue, a dominant interaction axis emerged between Macrophages and Aneuploid Renal Epithelial cells, notably involving EREG-EGFR and SIRPA-CD47. The EREG-EGFR interaction highlights a paracrine loop where tumor-associated macrophages (TAMs) may promote tumor cell proliferation, while the CD47-SIRPA interaction, a 'Don't eat me' signal, represents a critical mechanism for tumor cells to evade macrophage-mediated phagocytosis. Other significant interactions, such as IL10-IL10_receptor and PGE2-PTGER4, further underscore the immunosuppressive and pro-tumorigenic role of TAMs.

Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) unveiled profound metabolic reprogramming (Sections 13, 14). Normal renal epithelial cells are metabolically active, significantly enriching pathways like 'Oxidative phosphorylation', 'Citrate cycle', and 'Fatty acid degradation', reflecting their high energy demands for reabsorption. In stark contrast, tumor renal epithelial cells downregulate these oxidative pathways and upregulate processes associated with protein synthesis ('Ribosome', 'Protein processing in endoplasmic reticulum'), inflammation ('NF-kappa B signaling pathway'), and hypoxia ('HIF-1 signaling pathway'). This metabolic shift is characteristic of the Warburg effect and supports rapid tumor growth. Immune cells and stromal cells within the TME also show distinct metabolic adaptations, suggesting a complex metabolic symbiosis within the tumor.

Collectively, these findings paint a comprehensive picture of RCC progression, driven by genomic instability, immune landscape remodeling, active pro-tumorigenic cell-cell communication, and metabolic rewiring. These integrated insights provide a robust foundation for developing innovative diagnostic and therapeutic strategies.

Hypotheses:

1. The pervasive aneuploidy and specific copy number variations (e.g., EGFR amplification) observed in renal epithelial cells are direct drivers of renal cell carcinoma progression and contribute to tumor heterogeneity.
2. Tumor-associated macrophages (TAMs) actively promote the proliferation and survival of aneuploid renal epithelial cells in the tumor microenvironment through paracrine signaling, notably via the EREG-EGFR axis.
3. The CD47-SIRPA interaction serves as a primary mechanism by which renal cell carcinoma cells evade phagocytic clearance by macrophages, contributing to immune escape.
4. Metabolic reprogramming, characterized by reduced oxidative phosphorylation and increased macromolecule synthesis in tumor renal epithelial cells, is essential for tumor cell proliferation and survival, and is distinct from the metabolic profile of normal kidney cells.
5. The shift in T cell populations, specifically the relative decrease in CD8+ T cells and increase in CD4+ T cells, contributes to an immunosuppressive tumor microenvironment, hindering effective anti-tumor immunity in renal cell carcinoma.

Potential therapeutic targets:

1. EGFR: Recurrent amplification of the *EGFR* gene was observed in aneuploid renal epithelial tumor cells (Section 4), and a strong EREG-EGFR cell-cell interaction between macrophages and aneuploid renal epithelial cells suggests a critical paracrine loop promoting tumor cell proliferation and survival in the tumor microenvironment (Section 9, 11). Evidence: Genomic analysis showed *EGFR* amplification (7p13:7q11.23) in aneuploid tumor cells (Section 4, Image 5). CCI analysis identified EREG-EGFR as a highly significant interaction between Macrophages and Aneuploid Renal Epithelial cells in tumor conditions (Section 9, 11, Image 10, Image 12, Image 14). EGFR upregulation was also noted as a surfaceome marker in tumor renal epithelial cells (Section 12, Image 15). Validation: Assess the anti-tumorigenic effects of EGFR inhibitors in RCC *in vitro* (cell lines, organoids) and *in vivo* (xenograft or patient-derived xenograft models). Validate EREG expression by TAMs and EGFR expression by tumor cells using IHC/IF in patient samples. Evaluate patient response to EGFR-targeted therapies in clinical trials, correlating with *EGFR* amplification status.
2. CD47 / SIRPA: The CD47-SIRPA axis is a crucial 'Don't eat me' signaling pathway that enables cancer cells to evade phagocytic clearance by macrophages. Its identification as a strong interaction between aneuploid renal epithelial cells and macrophages in the tumor microenvironment suggests its role in immune evasion in RCC (Section 9). Evidence: CCI analysis revealed SIRPA-CD47 as a robust and widespread interaction between Macrophages and Aneuploid Renal Epithelial cells in tumor conditions (Section 9, Image 10). Validation: Test anti-CD47 or anti-SIRPA antibodies for their ability to enhance macrophage-mediated phagocytosis of RCC cells *in vitro*. Evaluate their efficacy in reducing tumor growth and metastasis *in vivo* in syngeneic or xenograft models, both as monotherapy and in combination with other immunotherapies (e.g., checkpoint inhibitors).
3. CXCR4: CXCR4, a chemokine receptor, was identified as an upregulated surfaceome marker in tumor renal epithelial cells. It is commonly involved in tumor growth, angiogenesis, and metastasis across various cancers (Section 12). Evidence: Surfaceome marker analysis showed CXCR4 upregulation in aneuploid renal epithelial cells from tumor samples (Section 12, Image 15). Validation: Investigate the impact of CXCR4 inhibition on RCC cell migration, invasion, and angiogenesis *in vitro*. Assess the anti-metastatic effects of CXCR4 antagonists in *in vivo* models of RCC. Correlate CXCR4 expression with metastatic potential in patient cohorts.
4. Metabolic Enzymes/Transporters (e.g., in Glycolysis, Amino Acid Metabolism): Gene Ontology and GSEA analyses revealed significant metabolic reprogramming in tumor renal epithelial cells, characterized by a shift away from oxidative phosphorylation towards pathways supporting biomass synthesis, such as altered glycolysis and amino acid metabolism (Sections 13, 14). Evidence: GSA for 'tumor_vs_others' showed upregulation of 'Ribosome', 'Protein processing in endoplasmic reticulum' and downregulation of 'Oxidative phosphorylation', 'Fatty acid degradation' (Section 13, Image 18). GSEA showed enrichment of 'Arginine and proline metabolism', 'Glycine, serine and threonine metabolism', 'Thiamine metabolism', 'Tryptophan metabolism', and 'Tyrosine metabolism' in tumor-associated cells (Section 14, Image 19). Validation: Identify specific enzymes or transporters within these altered metabolic pathways using multi-omics data. Test the selective inhibition of these targets on RCC cell viability, proliferation, and metabolic flux *in vitro*. Evaluate their anti-tumor efficacy and specificity *in vivo* using mouse models, ensuring minimal toxicity to normal kidney function.

Follow-up validation ideas:

1. Functional Validation of Oncogenic CNVs (e.g., EGFR amplification): Perform CRISPR/Cas9-mediated gene editing to mimic *EGFR* amplification or overexpression in normal renal epithelial cell lines and assess its impact on proliferation, migration, and tumorigenicity *in vitro* and *in vivo*. Conversely, inhibit *EGFR* in RCC cell lines with *EGFR* amplification to confirm its oncogenic role.
2. Inhibition of EREG-EGFR Signaling: Utilize *in vitro* co-culture systems of primary renal epithelial tumor cells and tumor-associated macrophages from RCC patients, or *in vivo* xenograft models, to test the efficacy of EGFR inhibitors or EREG-blocking antibodies in reducing tumor cell proliferation and survival. Measure changes in downstream signaling pathways.
3. Blocking CD47-SIRPA Interaction: Employ *in vitro* phagocytosis assays with patient-derived RCC cells and macrophages, or *in vivo* murine models, using anti-CD47 or anti-SIRPA antibodies to assess the restoration of macrophage-mediated tumor cell clearance and its impact on tumor growth and metastasis. Evaluate combined therapy with immune checkpoint inhibitors.
4. Metabolic Pathway Perturbation: Conduct targeted metabolomics and stable isotope tracing experiments in RCC cell lines and patient-derived organoids to precisely quantify altered metabolic fluxes (e.g., glycolysis, oxidative phosphorylation, amino acid metabolism). Functionally test the impact of inhibiting key enzymes or transporters (identified from GSA/GSEA) on tumor cell growth and viability *in vitro* and *in vivo*.
5. Immunological Characterization of TME: Perform multi-spectral immunohistochemistry or flow cytometry on patient RCC tissue to precisely phenotype CD4+ and CD8+ T cell subsets (e.g., Treg, Th17, exhausted T cells) and their spatial distribution relative to tumor cells and macrophages. Correlate T cell subset ratios with patient prognosis and response to immunotherapies.
6. Spatial Transcriptomics for CCI Validation: Utilize spatial transcriptomics or high-plex imaging techniques (e.g., CODEX, IMC) on RCC tissue sections to spatially resolve and quantify key ligand-receptor interactions (e.g., EREG-EGFR, CD47-SIRPA) at the single-cell level, confirming their cell-type specificity and co-localization in the TME.

Limitations:

This study, while comprehensive, has several limitations:

1. Inferential Nature of CNV and Ploidy: Copy Number Variations and ploidy status are inferred from scRNA-seq data (obsm['X_cnv'], obs['ploidy_dec']), which provides an estimate rather than direct genomic sequencing results. While robust, these inferences could have limitations in detecting very small or mosaic genomic changes.
2. Inferred Cell-Cell Interactions: The cell-cell interaction analysis (CellPhoneDB) predicts potential ligand-receptor interactions based on gene expression. These interactions are inferential and require experimental validation (e.g., *in vitro* co-culture assays, receptor blocking experiments, *in vivo* perturbation studies) to confirm their functional significance.
3. Cross-sectional Data: The single-cell RNA-seq data provides a snapshot of the cellular and molecular landscape at a single time point. It does not capture the dynamic evolution of renal cell carcinoma or the real-time responses to therapeutic interventions.
4. Species Specificity: All data is derived from human samples, ensuring direct clinical relevance. However, validation in preclinical *in vivo* models often relies on mouse models, which may not perfectly recapitulate all aspects of human RCC biology.
5. Resolution of 'Unassigned' Cells: Despite extensive annotation, a subset of cells remains 'unassigned'. While CNV analysis suggests many aneuploid 'unassigned' cells are likely malignant, their precise identity and function remain less characterized and warrant further investigation.
6. Lack of Clinical Outcome Data: The study describes biological changes associated with RCC but does not directly correlate these findings with patient clinical outcomes (e.g., survival, recurrence, treatment response), limiting immediate prognostic or predictive conclusions.

16. Query List

1. Show and save UMAPs including condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in 2 columns.
2. Show and save major cell type scores on UMAP.
3. Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
4. Select Renal Epithelial cells and unassigned cells, group them by sample, show and save a CNV heatmap, and also show a summary of significantly amplified copy number regions.
5. Show and save CNV patterns on UMAP. Include major cell type, minor cell type, ploidy results, condition, and sample in 2 columns.
6. Show and save a population bar plot of minor cell types.
7. Show and save a subset population bar plot for T cells.
8. Select Renal Epithelial cells and unassigned cells, show and save their ploidy population in a bar plot.
9. Show and save cell-cell interaction patterns per condition, including Renal Epithelial cells, Fibroblasts, Macrophages, and T cells. Select up to 80 cell-cell interactions per condition.
10. Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
11. Show and save cell-cell interactions only for genes related to immune checkpoint and cell cycle pathways.
12. Show the condition-specific markers for tumor-origin cells (Renal Epithelial cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
13. Show Gene Ontology (GSA) analysis results for epithelial cells as bar plots and save the result.
14. Show and save Gene Set Enrichment Analysis results for key cell types (Endothelial cell, Macrophage, Renal Epithelial cell, Smooth muscle cell, T cell CD4+) as a dot plot. Use 'RdBu_r' for the color map and set n_pws_to_show = 80.